UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

 

FORM10-Q

 

(MarkOne)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 

Forthe quarterly period ended June 30, 2025

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Forthe transition period from _______________________to___________________________

 

CommissionFile Number: 001-42374

 

SYNERGYCHC CORP.

(Exactname of registrant as specified in its charter)

 

Nevada   99-0379440
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)
     

865 Spring Street

Westbrook, Maine

  04092
(Address of principal executive offices)   (Zip Code)

 

(207)321-2350

(Registrant’stelephone number, including area code)

 

Securitiesregistered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common stock, par value $0.00001 per share   SNYR   The Nasdaq Stock Market LLC

 

Indicateby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit such files). Yes ☒ No ☐

 

Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of August 12, 2025, there were 9,621,926 shares of common stock,par value $0.00001 per share, of the registrant issued and 9,441,853 shares outstanding.

 

 

 

 

 

 

TABLEOF CONTENTS 

 

PART I—FINANCIAL INFORMATION   1
Item 1. Financial Statements   1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   28
Item 3. Quantitative and Qualitative Disclosures About Market Risk   35
Item 4. Controls and Procedures   35
     
PART II—OTHER INFORMATION   36
Item 1. Legal Proceedings   36
Item 1A. Risk Factors   36
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   36
Item 3. Defaults Upon Senior Securities   36
Item 4. Mine Safety Disclosures   36
Item 5. Other Information   36
Item 6. Exhibits   37
     
SIGNATURES   38

 

i

 

 

PARTI—FINANCIAL INFORMATION

 

Item1. Financial Statements.

 

SynergyCHC Corp.

 

CondensedInterim Financial Statements

Forthe Three and Six Months Ended June 30, 2025 and 2024

Unaudited

(Expressedin U.S. Dollars)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1

 

 

MANAGEMENT’SRESPONSIBILITY FOR FINANCIAL REPORTING CONDENSED INTERIM FINANCIAL REPORTING

 

Theaccompanying unaudited condensed interim financial statements of Synergy CHC Corp. (“the Company”) have been prepared bymanagement in accordance with accounting principles generally accepted in the United States (GAAP). Management acknowledges responsibilityfor the preparation and presentation of the unaudited condensed interim financial statements, including responsibility for significantaccounting estimates and the choice of accounting principles and methods that are appropriate to the Company’s circumstances.

 

2

 

 

SynergyCHC Corp.

CondensedConsolidated Balance Sheets

 

   June 30,
2025
   December 31,
2024
 
   (unaudited)     
Assets        
Current Assets        
Cash and cash equivalents  $1,458,561   $687,920 
Restricted cash   100,000    100,000 
Accounts receivable, net   7,069,889    5,321,037 
Other receivables   2,025,094    1,999,637 
Loan receivable (related party)   4,427,883    4,375,059 
Prepaid expenses (including related party amount of $801,345 and $312,966, respectively)   2,064,094    1,859,563 
Inventory, net   2,364,158    1,716,552 
Total Current Assets   19,509,679    16,059,768 
           
Intangible assets, net   216,667    283,333 
           
Total Assets  $19,726,346   $16,343,101 
           
Liabilities and Stockholders’ Deficit          
Current Liabilities:          
Accounts payable and accrued liabilities (including payable to shareholderof $92,955 and $88,644, respectively)  $4,960,331   $5,191,868 
Income taxes payable   266,472    242,977 
Contract liabilities   4,887    24,252 
Short term loans payable, net of debt discount   1,894,857    7,725,272 
Current portion of long-term notes payable, net of debt discount anddebt issuance cost, shareholder   
-
    4,000,000 
Total Current Liabilities   7,126,547    17,184,369 
           
Long-term Liabilities:          
Notes payable, net of debt discount, shareholder   
-
    8,333,053 
Notes payable, net of debt discount   24,978,999    7,457,022 
Total long-term liabilities   24,978,999    15,790,075 
Total Liabilities   32,105,546    32,974,444 
           
Commitments and contingencies   
 
    
 
 
           
Stockholders’ Deficit:          
Common stock, $0.00001 par value; 300,000,000 shares authorized; 9,621,926 and 8,721,818, shares issued, respectively; 9,441,853 and 8,541,745 outstanding, respectively   96    87 
Additional paid in capital   29,508,354    27,643,660 
Accumulated other comprehensive loss   (9,838)   (47,777)
Accumulated deficit   (41,750,312)   (44,099,813)
Less: Treasury stock (180,073 shares) at cost   (127,500)   (127,500)
Total stockholders’ deficit   (12,379,200)   (16,631,343)
Total Liabilities and Stockholders’ Deficit  $19,726,346   $16,343,101 

 

Theaccompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

3

 

 

SynergyCHC Corp.

UnauditedCondensed Consolidated Statements of Income and Comprehensive Income

 

   For the three months ended   For the six months ended 
   June 30,
2025
   June 30,
2024
   June 30,
2025
   June 30,
2024
 
Revenue                
Product Sales  $6,734,996   $8,024,840   $13,405,530   $17,436,703 
License Revenue   1,400,000    
-
    2,900,000    
-
 
Total Revenue   8,134,996    8,024,840    16,305,530    17,436,703 
                     
Cost of sales   1,896,391    2,448,890    3,902,904    5,086,029 
Gross profit   6,238,605    5,575,950    12,402,626    12,350,674 
                     
Operating expenses                    
Selling and marketing   3,062,211    3,055,186    5,938,482    6,639,863 
General and administrative   1,519,325    903,838    2,826,039    2,252,223 
Depreciation and amortization   33,334    33,334    66,667    66,667 
Total operating expenses   4,614,870    3,992,358    8,831,188    8,958,753 
                     
Income from operations   1,623,735    1,583,592    3,571,438    3,391,921 
                     
Other (income) expenses                    
Other income                    
Interest income   (379)   (374)   (14,261)   (761)
Interest expense   2,107,714    745,528    3,203,083    1,855,508 
Gain on settlement of notes payable   (2,154,522)   
-
    (2,154,522)   
-
 
Remeasurement (gain) loss on translation of foreign subsidiary   7,578    3,870    8,990    (5,113)
                     
Total other (income) expenses   (39,609)   749,024    1,043,290    1,849,634 
                     
Net income before income taxes   1,663,344    834,568    2,528,148    1,542,287 
Income tax benefit (expense)   (190,107)   (179,382)   (178,647)   (306,571)
Net income after tax  $1,473,237   $655,186   $2,349,501   $1,235,716 
                     
Net income per share – basic  $0.17   $0.09   $0.27   $0.17 
Net income per share – diluted  $0.17   $0.09   $0.27   $0.17 
                     
Weighted average common shares outstanding                    
Basic   8,928,548    7,373,745    8,743,639    7,373,745 
Diluted   8,928,548    7,373,745    8,743,639    7,373,745 
                     
Comprehensive income:                    
Net income   1,473,237    655,186    2,349,501    1,235,716 
Foreign currency translation adjustment   39,874    55,736    37,939    187,373 
Comprehensive income  $1,513,111   $710,922   $2,387,440   $1,423,089 

 

Theaccompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

4

 

 

SynergyCHC Corp.

UnauditedCondensed Consolidated Statement of Stockholders’ Deficit

 

   Common stock   Additional
Paid in
   Accumulated
Other
Comprehensive
Income
   Treasury   Accumulated   Total
Stockholders’
 
   Shares   Amount   Capital   (Loss)   stock   Deficit   Deficit 
Balance as of December 31, 2023   7,553,818   $76   $19,148,707   $(102,467)  $(127,500)  $(46,224,789)  $(27,305,973)
Foreign currency translation gain                  131,637              131,637 
Net income                            580,530    580,530 
Balance as of March 31, 2024   7,553,818   $76   $19,148,707   $29,170   $(127,500)  $(45,644,259)  $(26,593,806)
Fair value of vested stock options             4,611                   4,611 
Foreign currency translation gain                  55,736              55,736 
Net income                            655,186    655,186 
Balance as of June 30, 2024   7,553,818   $76   $19,153,318   $84,906   $(127,500)  $(44,989,073)  $(25,878,273)

 

   Common stock   Additional
Paid in
   Accumulated
Other
Comprehensive
Income
   Treasury   Accumulated   Total
Stockholders’
 
   Shares   Amount   Capital   (Loss)   stock   Deficit   Deficit 
Balance as of December 31, 2024   8,721,818   $87   $27,643,660   $(47,777)  $(127,500)  $(44,099,813)  $(16,631,343)
Foreign currency translation loss                  (1,935)             (1,935)
Issuance of common stock for loan financing   30,360    1    117,647                   117,648 
Net income                            876,264    876,264 
Balance as of March 31, 2025   8,752,178   $88   $27,761,307   $(49,712)  $(127,500)  $(43,223,549)  $(15,639,366)
Foreign currency transaction gain                  39,874              39,874 
Issuance of pre-funded warrants for settlement of shareholder notes payable             899,993                   899,993 
Issuance of common stock for exercise of pre-funded warrants   428,570    4    (4)                  
-
 
Issuance of common stock for modification of notes payable   441,178    4    847,058                   847,062 
Net income                            1,473,237    1,473,237 
Balance as of June 30, 2025   9,621,926   $96   $29,508,354   $(9,838)  $(127,500)  $(41,750,312)  $(12,379,200)

 

Theaccompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

5

 

 

SynergyCHC Corp.

UnauditedCondensed Consolidated Statements of Cash Flows 

 

   For the six
months ended
   For the six months ended 
   June 30,
2025
   June 30,
2024
 
Cash Flows from Operating Activities        
Net income  $2,349,501   $1,235,716 
Adjustments to reconcile net income to net cash used in operating activities:          
Amortization of debt discount and debt issuance cost   892,435    
-
 
Depreciation and amortization   66,667    66,667 
Stock based compensation   
-
    4,611 
Stock issued for modification of notes payable   847,062    
-
 
Foreign currency transaction loss (gain)   (9,068)   23,345 
Remeasurement loss (gain) on translation of foreign subsidiary   8,990    (5,113)
Non cash implied interest   
-
    4,799 
Gain on settlement of debt   (2,154,522)   
-
 
Changes in operating assets and liabilities:          
Accounts receivable   (1,748,852)   (1,161,992)
Other receivables   (25,457)   
-
 
Loan receivable, related party   (52,824)   35,449 
Inventory   (647,606)   1,805,950 
Prepaid expenses   283,848    (276,818)
Prepaid expense, related party   (488,379)   (326,682)
Income taxes payable   23,495    262,374 
Contract liabilities   (19,365)   (2,949)
Accounts payable and accrued liabilities   (610,770)   (2,804,381)
Accounts payable, shareholder   385,114    (980)
Net cash used in operating activities   (899,731)   (1,140,005)
           
Cash Flows from Investing Activities   
-
    
-
 
           
Cash Flows from Financing Activities          
Advances from related party   135,000    1,509,226 
Repayment of notes payable, related party   (135,000)   (84,500)
Proceeds from notes payable   18,996,250    600,000 
Payment of loan financing fees   (1,980,914)   
-
 
Repayment of notes payable, shareholder   (10,000,000)   
-
 
Repayment of notes payable   (5,382,903)   (1,617,335)
Net cash provided by financing activities   1,632,433    407,391 
           
Effect of exchange rate on cash, cash equivalents and restricted cash   37,939    187,373 
Net increase (decrease) in cash, cash equivalents and restricted cash   770,641    (545,241)
           
Cash and restricted cash, beginning of year   787,920    732,534 
Cash and restricted cash, end of period  $1,558,561   $187,293 
           
Supplemental Disclosure of Cash Flow Information:          
Cash paid during the period for:          
Interest  $896,734   $1,850,896 
Income taxes  $
-
   $44,197 
           
Supplemental Disclosure of Noncash Investing and Financing Activities:          
Accounts payable converted to loan payable upon settlement  $
-
   $3,770,824 
Reduction of short term related party note payable by reduction of prepaid balance  $
-
   $328,003 
Issuance of common stock for loan financing  $117,648   $
-
 
Issuance of pre-funded warrants for settlement of shareholder notes payable  $899,993   $
-
 
Exercise of pre-funded warrants  $4   $
-
 
Loan fees payable to lender  $375,000   $
-
 

 

Theaccompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

6

 

 

SynergyCHC Corp.

NOTESTO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Note1 – Nature of the Business

 

SynergyCHC Corp. (“Synergy”, “we”, “us”, “our” or the “Company”) (formerly SynergyStrips Corp.) was incorporated on December 29, 2010 in Nevada under the name “Oro Capital Corporation.” On April 21, 2014,the Company changed its fiscal year end from July 31 to December 31. On April 28, 2014, the Company changed its name to “SynergyStrips Corp.”. On August 5, 2015, the Company changed its name to “Synergy CHC Corp.”

 

TheCompany is a consumer health care company that is in the process of building a portfolio of best-in-class consumer product brands. Synergy’sstrategy is to grow its portfolio both organically and by further acquisitions.

 

EffectiveJanuary 1, 2019 the Company has merged its U.S. subsidiaries (Neuragen Corp., Breakthrough Products, Inc., Sneaky Vaunt Corp., and TheQueen Pegasus Corp.) into the parent company.

 

Synergyis the sole owner of four subsidiaries: NomadChoice Pty Ltd., Hand MD Corp., Synergy CHC Inc. and Synergy CHC Mexico, and the resultshave been consolidated in these statements. Synergy CHC Mexico was incorporated during May 2025 for the purposes of expanding into Mexico.

 

Note2 – Summary of Significant Accounting Policies

  

Basisof Presentation

 

Theaccompanying condensed consolidated financial statements as of June 30, 2025 and for the three and six months ended June 30, 2025 and2024 are unaudited. The accompanying consolidated financial statements have been prepared in conformity with accounting principles generallyaccepted in the United States of America (“US GAAP”). Accordingly, they do not include all the information and footnotesrequired by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments(consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for thethree and six months ended June 30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year endingDecember 31, 2025. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidatedfinancial statements as of and for the year ended December 31, 2024 and footnotes thereto.

 

Allamounts referred to in the notes to the consolidated financial statements are in United States Dollars ($) unless stated otherwise.

 

Theconsolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompanybalances and transactions have been eliminated in consolidation.

 

ReverseStock Split

 

OnSeptember 11, 2024, the Company effected a 1-for-11.9 reverse stock split with respect to its common stock. The reverse stock split didnot change the number of authorized shares of common stock or par value. All references in these condensed consolidated financial statementsto shares, share prices, exercise prices and other per share information in all periods have been adjusted, on a retroactive basis, toreflect the reverse stock split.

 

Useof Estimates

 

Thepreparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptionsthat affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statementsand the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimatesincluded are assumptions about collection of accounts receivable, current income taxes, deferred income taxes valuation allowance, usefullife of intangible assets, impairment analysis of intangible assets, estimates used in the fair value calculation of stock based compensation,assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate and expecteddividend rate, accrual of sales returns, and accrual of legal expense. The results of any changes in accounting estimates are reflectedin the financial statements in the period in which the changes become evident. Estimates and assumptions are reviewed periodically, andthe effects of revisions are reflected in the period that they are determined to be necessary.

 

7

 

 

Cashand Cash Equivalents

 

TheCompany considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquidinvestments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of June 30, 2025 and December31, 2024, the Company had no cash equivalents. The Company maintains its cash in banks insured by the Federal Deposit Insurance Corporation(FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this riskby placing its cash deposits with major financial institutions. At June 30, 2025 and December 31, 2024, the uninsured balances amountedto $1,286,994 and $503,215, respectively.

 

RestrictedCash

 

Thefollowing table provides a reconciliation of cash and restricted cash reported within the statement of financial position that sum tothe total of the same such amounts shown in the statement of cash flows.

 

   June 30,
2025
   December 31,
2024
 
         
Cash  $1,458,561   $687,920 
Restricted cash   100,000    100,000 
Total cash and restricted cash shown in the statement of cash flows  $1,558,561   $787,920 

 

Amountsincluded in restricted cash represent amounts held for credit card collateral.

 

IntangibleAssets

 

TheCompany evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revisedestimates of useful lives or that indicate that impairment exists. All of the intangible assets are subject to amortization. Intangibleassets are amortized on a straight-line basis over the useful lives.

 

Long-livedAssets

 

Long-livedassets include intangible assets other than those with indefinite lives. The Company assesses the carrying value of its long-lived assetgroups when indicators of impairment exist and recognizes an impairment loss when the carrying amount of a long-lived asset is not recoverablewhen compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset.

 

Indicatorsof impairment include significant underperformance relative to historical or projected future operating results, significant changesin the Company’s use of the assets or in its business strategy, loss of or changes in customer relationships and significant negativeindustry or economic trends. When indications of impairment arise for a particular asset or group of assets, the Company assesses thefuture recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying valueexceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or assetgroup), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value.

 

RevenueRecognition

 

TheCompany recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting StandardsCodification (“ASC”) ASC 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized whencontrol is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchangefor those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts,with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv)allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performanceobligation is satisfied.

 

8

 

 

TheCompany recognizes revenue upon shipment from its fulfillment centers. Certain of the Company’s distributors may also perform aseparate function as a co-packer on the Company’s behalf. In such cases, ownership of and title to the Company’s productsthat are co-packed on the Company’s behalf by those co-packers who are also distributors, passes to such distributors when theCompany is notified by them that they have taken transfer or possession of the relevant portion of the Company’s finished goods.Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Cancelled ordersare refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specificpromotions and orders will be refilled if lost in transit.  The Company recognizes revenue for its digital products in the monththe download by the customer occurs. 

 

Allproduct sales were initiated based upon the retailer’s purchase orders at a fixed transaction price and revenues recognized whenthe products were shipped to the Company’s customers.

 

TheCompany accounts for its IP license revenue, which provides the Company’s customer with rights to use the Company’s IP, inaccordance with ASC 606. A license may be perpetual or time limited in its application. In accordance with ASC 606, the Company willcontinue to recognize revenue from IP license at the time of delivery when the customer accepts control of the IP, as the IP is functionalwithout professional services, updates and technical support. The Company has concluded that its IP license is distinct as the customercan benefit from the functional IP on its own. Therefore, the Company has determined the right to use its IP was satisfied at a pointin time (on the date the rights to the IP were granted).

 

ContractAssets

 

TheCompany does not have any contract assets such as work-in-process. All trade receivables on the Company’s condensed consolidatedbalance sheet are from contracts with customers.

 

ContractCosts

 

Costsincurred to obtain a contract are capitalized unless short term in nature. As a practical expedient, costs to obtain a contract thatare short term in nature are expensed as incurred. The Company does not have any contract costs capitalized as of June 30, 2025 and December31, 2024.

 

ContractLiabilities

 

TheCompany’s contract liabilities consist of advance customer payments. Contract liability results from transactions in which theCompany has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenuerecognition criteria have been met, the contract liabilities are recognized.

 

   June 30,
2025
   December 31,
2024
 
         
Beginning balance  $24,252   $14,202 
Additions   4,887    24,252 
Recognized as revenue   (24,252)   (14,202)
Ending balance  $4,887   $24,252 

 

Accountsreceivable

 

Accountsreceivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstandinginvoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have beenexhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance fordoubtful accounts. As of both June 30, 2025 and December 31, 2024, allowance for doubtful accounts was $0.

 

AdvertisingExpense

 

TheCompany expenses marketing, promotions and advertising costs as incurred. Such costs are included in selling and marketing expense inthe accompanying consolidated statements of operations.

 

Researchand Development

 

Costsincurred in connection with the development of new products and processing methods are charged to general and administrative expensesas incurred.

 

9

 

 

IncomeTaxes

 

TheCompany utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities forthe expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method,deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and theirfinancial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences areexpected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred taxasset will not be realized.

 

TheCompany generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been establisheddue to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration.

 

NomadChoicePty Ltd, the Company’s wholly-owned subsidiary is subject to income taxes in the jurisdictions in which it operates. Significantjudgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during theordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipatedtax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is differentfrom the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determinationis made.

 

SynergyCHC Inc., a wholly-owned foreign subsidiary, is subject to income taxes in the jurisdictions in which it operates. Significant judgmentis required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinarycourse of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax auditissues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different fromthe carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determinationis made. 

 

NetEarnings (Loss) Per Common Share

 

The Company computes earnings per share under ASC subtopic 260-10,Earnings Per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders(the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Dilutedearnings per share is computed by increasing the denominator by the weighted average number of additional shares that could have beenoutstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on netincome per share is anti-dilutive. As of June 30, 2025 and 2024, options to purchase 252,102 and 336,134 shares of common stock, respectively,were outstanding. As of June 30, 2025, warrants to purchase 103,500 shares of common stock were outstanding.

 

Thefollowing is a reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the three andsix months ended June 30, 2025 and 2024:

 

   For the three months ended   For the six months ended 
   June 30,
2025
   June 30,
2024
   June 30,
2025
   June 30,
2024
 
                 
Net income after tax  $1,473,237   $655,186   $2,349,501   $1,235,716 
                     
Weighted average common shares outstanding   8,928,548    7,373,745    8,743,639    7,373,745 
Incremental shares from the assumed exercise of dilutive stock options   
-
    
-
    
-
    
-
 
Dilutive potential common shares   8,928,548    7,373,745    8,743,639    7,373,745 
                     
Net earnings per share:                    
Basic  $0.17   $0.09   $0.27   $0.17 
Diluted  $0.17   $0.09   $0.27   $0.17 

 

10

 

 

Thefollowing securities were not included in the computation of diluted net earnings per share as their effect would have been antidilutive:

 

   For the three and six months ended 
   June 30,
2025
   June 30,
2024
 
         
Options to purchase common stock   252,102    336,134 
Warrants to purchase common stock   103,500    - 

 

FairValue Measurements

 

TheCompany measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820,Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fairvalue measurement disclosure.

 

ASC825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transactionbetween market participants at the measurement date. When determining the fair value measurements for assets and liabilities requiredor permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transactand considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions,and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputsand minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used tomeasure fair value:

 

Level1 - Quoted prices for identical assets or liabilities in active markets to which the Company has access at the measurement date.

 

Level2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.

 

Level3 - Unobservable inputs for the asset or liability. 

 

Thedetermination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significantto the fair value measurement.

 

Our financial instruments consisted primarilyof cash and cash equivalents, restricted cash, accounts receivable, other receivable, loan receivable, accounts payable and accrued liabilitiesand short term and long term loans payable. The carrying amounts of such financial instruments approximate their respective estimatedfair value due to the short-term maturities and approximate market interest rates of these instruments.

 

As of both June 30, 2025 and December 31, 2024, the Company has determinedthat there were no assets or liabilities measured at fair value on a recurring basis.

 

Inventory

 

Inventoryconsists of raw materials, components and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis)or net realizable value. Finished goods include the cost of labor to assemble the items.

 

ForeignCurrency Translation

 

Thefunctional currency of one of the Company’s foreign subsidiaries (NomadChoice Pty Ltd.) is the U.S. Dollar. The Company’sforeign subsidiary maintains its records using local currency (Australian Dollar). All monetary assets and liabilities of the foreignsubsidiary were translated into U.S. Dollars at quarter end exchange rates, non-monetary assets and liabilities of the foreign subsidiarywere translated into U.S. Dollars at transaction day exchange rates.

 

Incomeand expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomesand expenses were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes,were recorded in statements of operations as Remeasurement gain or loss on translation of foreign subsidiary.

 

Thefunctional currency of the Company’s other foreign subsidiary (Synergy CHC Inc.) is the Canadian Dollar (CAD). The Company’sforeign subsidiary maintains its records using local currency (CAD). All assets and liabilities of the foreign subsidiary were translatedinto U.S. Dollars at period end exchange rates and stockholders’ equity is translated at the historical rates. Income and expenseitems were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, are reportedas other comprehensive income and accumulated other comprehensive income in the stockholder’s equity in accordance with ASC 220– Comprehensive Income.

 

11

 

 

Theexchange rates used to translate amounts in AUD and CAD into USD for the purposes of preparing the consolidated financial statementswere as follows:

 

Balancesheet:

 

   June 30,
2025
   December 31,
2024
 
Period-end AUD: USD exchange rate  $0.6572   $0.6183 
Period-end CAD: USD exchange rate  $0.7330   $0.6950 

 

Incomestatement:

 

   June 30,
2025
   June 30,
2024
 
Average six months AUD: USD exchange rate  $0.6338   $0.6585 
Average six months CAD: USD exchange rate  $0.7098   $0.7361 
Average three months AUD: USD exchange rate  $0.6403   $0.6591 
Average three months CAD: USD exchange rate  $0.7226   $0.7308 

 

Translationgains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currencyare translated into either Australian Dollars or Canadian Dollars, as the case may be, at the rate on the date of the transaction andincluded in the results of operations as incurred.

 

Concentrationsof Credit Risk

 

Inthe normal course of business, the Company provides credit terms to its customers; however, collateral is not required. Accordingly,the Company performs credit evaluations of its customers and maintains allowances for possible losses which, when realized, were withinthe range of management’s expectations. From time to time, a higher concentration of credit risk exists on outstanding accountsreceivable for a select number of customers due to individual buying patterns.

 

Warehousingcosts

 

Warehousecosts include all third-party warehouse rent fees and are charged to selling and marketing expenses as incurred. Any additional costsrelating to assembly or special pack-outs of the Company’s products are charged to cost of sales.

 

Productdisplay costs

 

Alldisplays manufactured and purchased by the Company are for placement of product in retail stores. This also includes all costs for displayexecution and setup and retail services are charged to cost of sales and expensed as incurred.

 

Costof Sales

 

Costof sales includes the purchase cost of products sold, all costs associated with getting the products into the retail stores includingbuying and transportation costs and the hosting of the Company’s online Application. 

 

DebtIssuance Costs

 

Debtissuance costs consist primarily of arrangement fees, professional fees and legal fees. These costs are netted off with the related loanand are being amortized to interest expense over the term of the related debt facilities.

 

ShippingCosts

 

Shippingand handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling and marketingexpenses.

 

12

 

 

Relatedparties

 

Partiesare considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control,are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management,members of the immediate families of principal owners of the Company and its management and other parties with which the Company maydeal if one party controls or can significantly influence the management or operating policies of the other to an extent that one ofthe transacting parties might be prevented from fully pursuing its own separate interests (see Note 9).

 

SegmentReporting

 

Segmentidentification and selection is consistent with the management structure used by the Company’s chief executive officer who is theChief Operating Decision Maker (CODM) to evaluate performance and make decisions regarding resource allocation, as well as the materialityof financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting,the Company has one operating segment. The Company derives its revenue from the sale of nutraceuticals. The accounting policiesof the segment are the same as those described in the summary of significant accounting policies. The chief operating decision makerassesses performance for the segment and decides how to allocate resources based on net income that also is reported on the income statementas consolidated net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. Significantsegment expenses include retailer promotions, freight and fulfillment, marketing and salaries. The Company’s CODM reviews financialinformation presented and decides how to allocate resources based on net income. The Company does have intra-entity sales or transfers.The Company’s CODM does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviewsoperating results on an aggregated basis. 

  

Presentationof Financial Statements – Going Concern

 

GoingConcern Evaluation

 

Inconnection with preparing unaudited condensed consolidated financial statements for the six months ended June 30, 2025, management evaluatedwhether there were conditions and events, considered in the aggregate, that raised substantial doubt about the Company’s abilityto continue as a going concern within one year from the date that the unaudited condensed consolidated financial statements are issued.

 

TheCompany considered the following:

 

  At June 30, 2025, the Companyhad an accumulated deficit of $41,750,312.

 

  During the six months ended June 30, 2025, there was a decrease in revenue of $1,131,173.

 

  During the six months ended June 30, 2025, the Company had $899,731 of net cash used in operating activities

 

Ordinarily,conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern relate to the entity’sability to meet its obligations as they become due.

 

TheCompany evaluated its ability to meet its obligations as they become due within one year from the date that the financial statementsare issued by considering the following:

 

  At June 30, 2025, the Company had working capital surplus of $12,383,132.

 

  During the six months ended June 30, 2025, the Company refinanced a portion of its outstanding debts to one lender with favorable terms (see Note 11).

 

  During the six months ended June 30, 2025, the Company had net income of $2,349,501.

 

  The Company has the option of publicly selling its common stock to raise additional capital.

 

  The Company has the option of selling any of its brands to raise additional capital.

  

Managementconcluded that above factors alleviate doubts about the Company’s ability to generate enough cash from operations and other availablesources to satisfy its obligations for the next twelve months from the issuance date.

 

13

 

 

TheCompany will take the following actions if it starts to trend unfavorably to its internal profitability and cash flow projections, inorder to mitigate conditions or events that would raise substantial doubt about its ability to continue as a going concern:

 

  Raise additional capital through line of credit and/or loans financing for future mergers and acquisitions.

 

  Implement restructuring and cost reductions.

 

  Raise additional capital through an additional capital raise.

 

Correctionof Prior Period Immaterial Errors:

 

TheCompany has identified an immaterial error in the Company’s previously issued consolidated financial statements related to Treasury Sharesheld by its wholly owned subsidiary. The adjustment pertained to the acquisition of remaining 50% ownership interest in Hand MD Corp.during July 2021 and accordingly the shares previously issued to Hand MD Corp. required correction on the financial statement as Treasury Shareson the consolidated balance sheet. The amount of the reclassification is $127,500 and has no effect on the consolidated statementof income and other comprehensive income (except for earnings per share and weighted average shares) and statement of cash flow.

 

Inevaluating whether the previously issued consolidated financial statements were materially misstated for the interim or annual periodsprior to December 31, 2022, the Company applied the guidance of ASC 250, Accounting Changes and Error Corrections, SEC StaffAccounting Bulletin (“SAB”) Topic 1.M, Assessing Materiality and SAB Topic 1.N, Considering the Effects of PriorYear Misstatements when Quantifying Misstatements in Current Year Financial Statements, and concluded that the effect of the errorson prior period annual financial statements was immaterial. The guidance states that prior-year misstatements which, if corrected inthe current year would materially misstate the current year’s financial statements, must be corrected by adjusting prior year financialstatements, even though such correction previously was and continues to be immaterial to the prior-year financial statements. Correctingprior-year financial statements for such immaterial misstatements does not require previously filed reports to be amended.

 

TheCompany’s earnings per share has been revised from the amounts previously reported to correct the error and the impact of the reclassification isshown in the below table.

  

EarningsPer Share for the six months ended June 30, 2024:

 

   As Previously         
   Reported   Corrections   As Adjusted 
             
Earnings per share  $0.16   $0.01   $0.17 
Weighted average common shares outstanding   7,553,818    (180,073)   7,373,745 

 

EarningsPer Share for the three months ended June 30, 2024:

 

   As Previously         
   Reported   Corrections   As Adjusted 
             
Earnings per share  $0.08   $0.01   $0.09 
Weighted average common shares outstanding   7,553,818    (180,073)   7,373,745 

 

RecentAccounting Pronouncements  

 

InDecember 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No.2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 amendsthe rules on income tax disclosures to require entities to disclose specific categories in the rate reconciliation, the income or lossfrom continuing operations before income tax expense or benefit (separated between domestic and foreign) and income tax expense or benefitfrom continuing operations (separated by federal, state, and foreign). In addition, ASU 2023-09 requires entities to disclose their incometax payments to international, federal, state, and local jurisdictions, among other changes. The amendments can be applied on a prospectivebasis although retrospective application is permitted. The amendments are effective for the fiscal years beginning after December 15,2024, with early adoption permitted. The adoption of ASU 2023-09 has not affected the Company’s financial statements.

  

InOctober 2023, the FASB issued ASU No. 2023-06, “Disclosure Improvements: Codification Amendments in Response to the SEC’sDisclosure Update and Simplification Initiative” (“ASU 2023-06”). ASU 2023-06 amends U.S. GAAP to reflect updates andsimplifications to certain disclosure and presentation requirements referred to FASB by the Securities and Exchange Commission (“SEC”).The targeted amendments incorporate 14 of the 27 disclosures referred by the SEC into codification. Each amendment in ASU 2023-06 iseffective on either the date on which the SEC’s removal of the related disclosure requirement from Regulation S-X or RegulationS-K becomes effective, or on June 30, 2027, if the SEC has not removed the requirements by that date. The Company is currently evaluatingthe impact this update will have on its Consolidated Financial Statements. 

 

14

 

 

Note3 – Income Taxes 

 

TheCompany utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities forthe expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method,deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and theirfinancial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences areexpected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred taxasset will not be realized.

 

Deferredincome taxes arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposesin different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilitiesto which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classifiedas current or noncurrent depending on the periods in which the temporary differences are expected to reverse. The Company does not haveany uncertain tax positions.

 

ForU.S. purposes, the Company has not completed its evaluation of NOL utilization limitations under Internal Revenue Code, as amended (the“Code”) Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOL’s would belimited or eliminated, as to the amount that could be utilized each year, based on the Code. NOL’s attributable to BreakthroughProducts, Inc., which are the majority of the Company’s domestic NOL’s are Separate Return Limitation Year (SRLY) NOL’s.Such losses may generally not be available for use (limited or eliminated).

 

TheCompany has not filed its State & Local Income/Franchise tax returns in states it is required to file, as such returns and liabilityremain open. The Company does not expect this to be a significant liability. 

 

The Company had tax expense of $178,647 and $306,571for the six months ended June 30, 2025 and 2024, respectively. The Company had tax expense of $190,107 and $179,382 for the three monthsended June 30, 2025 and 2024, respectively. The Company’s provision for tax expense amount, computed by applying the statutory federalincome tax rate of 21% in 2025 and 2024 to income before taxes, differs from the effective tax rate, due primarily to state income taxesand permanent items (plus utilization of NOL carryforwards in 2023).

 

The Company also has net operating loss carryforwardsof approximately $48,700,000 and approximately $50,800,000 (United States, Canada and Australia) included in the deferred tax assets forJune 30, 2025 and December 31, 2024, respectively, the majority attributable to the acquisition of Breakthrough Products, Inc. However,due to limitations of carryover attributes and separate return limitation year rules, it is unlikely the company will benefit from theNOLs and thus Management has determined a 100% valuation allowance is required. Further, the Company has not completed an evaluationof the NOLs attributable to Breakthrough Products, Inc. at the date of this report.

 

Note4 – Accounts Receivable

 

Accountsreceivable, net of allowances for doubtful accounts, consisted of the following:

 

   June 30,
2025
   December 31,
2024
 
Trade accounts receivable  $7,069,889   $5,321,037 
Other receivables   2,025,094    1,999,637 
Less allowances   -    - 
Total accounts receivable, net  $9,094,983   $7,320,674 

 

Duringthe three and six months ended June 30, 2025 and 2024, the Company charged $0 to bad debt expense.

 

15

 

 

Note5 – Prepaid Expenses

 

AtJune 30, 2025 and December 31, 2024, prepaid expenses consisted of the following:

 

   June 30,
2025
   December 31,
2024
 
Advances for inventory  $260,572   $605,913 
Insurance   36,429    2,879 
Deposits   14,000    14,000 
Prepaid consulting fees, related party   695,587    296,981 
Rent, related party   105,757    15,985 
Advertising and promotions*   859,920    869,920 
Conferences   9,500    15,000 
Professional fees   41,000    13,000 
IT expenses   33,479    25,404 
Miscellaneous   7,850    481 
Total  $2,064,094   $1,859,563 

 

* During the year ended December 31, 2024, the Company bartered inventory worth $859,920 for media credits to be used at the Company’s discretion.

  

Note6 – Concentration of Credit Risk

 

Cashand cash equivalents

 

TheCompany maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts thatat times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash depositswith major financial institutions. At June 30, 2025 and December 31, 2024, the uninsured balances amounted to $1,286,994 and $503,215respectively.

 

Accountsreceivable

 

Asof June 30, 2025 and December 31, 2024, two and one customers accounted for 84% and 74%, respectively, of the Company’s trade accountsreceivable.

 

Majorcustomers

 

Forthe six months ended June 30, 2025, three customers accounted for approximately 80% of the Company’s net revenue. For the six monthsended June 30, 2024, two customers accounted for approximately 70% of the Company’s net revenue. For the three months ended June30, 2025, three customers accounted for approximately 82% of the Company’s net revenue. For the three months ended June 30, 2024,two customers accounted for approximately 72% of the Company’s net revenue. Substantially all of the Company’s business iswith companies in the United States.

 

16

 

 

Accountspayable

 

Asof June 30, 2025 and December 31, 2024, two and four vendors accounted for 58% and 69%, respectively, of the Company’s accountspayable.

 

Majorsuppliers

 

Forthe six months ended June 30, 2025, three suppliers accounted for approximately 47% of the Company’s purchases. For the six monthsended June 30, 2024, one supplier accounted for approximately 21% of the Company’s purchases. For the three months ended June 30,2025, one supplier accounted for approximately 39% of the Company’s purchases. For the three months ended June 30, 2024, one supplieraccounted for approximately 13% of the Company’s purchases. Substantially all of the Company’s business is with suppliersin the United States.

 

Note7 – Inventory

 

Inventoryconsists of finished goods, components and raw materials. The Company’s inventory is stated at the lower of cost (FIFO cost basis)or net realizable value.

 

Thecarrying value of inventory consisted of the following:

 

   June 30,
2025
   December 31,
2024
 
Finished goods  $2,213,770   $1,578,561 
Components   105,388    92,991 
Raw materials   45,000    45,000 
Total inventory  $2,364,158   $1,716,552 

 

Duringthe six months ended June 30, 2025 and 2024, the Company had no inventory write-offs.  

 

Note8 – Intangible Assets

  

   June 30,
2025
   December 31,
2024
 
         
License Fee  $450,000   $450,000 
Less accumulated amortization   (233,333)   (166,667)
Intangible assets, net  $216,667   $283,333 

 

Amortizationfor the six months ended June 30, 2025 and 2024 was $66,666 and $66,667, respectively.

 

Theestimated aggregate amortization expense over each of the next five years is as follows:

 

2025 (remaining)  $66,667 
2026   133,333 
2027   16,667 

 

Note9 – Related Party Transactions

 

The Company paid consulting fees through June2025 to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company. The Company expensed $0 during the three and six monthsended June 30, 2025 and 2024 as consulting fees. The Company advanced $398,606 and $326,683 in prepaid consulting fees during the sixmonths ended June 30, 2025 and 2024, respectively. The prepaid balance as of June 30, 2025 and December 31, 2024 was $695,587 and $296,981,respectively. During the six months ended June 30, 2025 and 2024, the Company was advanced $135,000 and $1,400,000, respectively, in theform of a short-term note. During the six months ended June 30, 2025 the Company repaid the $135,000 advance. The balance owed as of bothJune 30, 2025 and December 31, 2024 was $0. During the three months ended June 30, 2025, the Company paid $53,720 in the manner of prepaidrent for one year. The Company expensed $4,477 during the six months ended June 30, 2025, leaving a prepaid balance of $49,243.

 

The Company paid rent through June 2025 to a companyowned by Mr. Jack Ross, Chief Executive Officer of the Company. The Company expensed $60,000 Canadian Dollars ($42,587 US Dollars) forthe six months ended June 30, 2025, leaving a prepaid balance of $77,100 Canadian Dollars ($53,514 US Dollars).

 

17

 

 

The Company entered into transactions with a relatedparty controlled by the CEO during prior years. The transactions were a pass through and allocation of expenses and reimbursements. As of June 30, 2025 and December 31, 2024 the Company was owed $4,427,883 and $4,375,059, respectively. This loan has a repayment dateof December 31, 2025. If the loan is not repaid by January 1, 2026, the borrower will pledge the number of shares of borrower’sstock with a market value equal to the amount outstanding on the note as security to be released upon payment of the note.

 

TheCompany entered into a transaction with a related party controlled by the CEO during the year ended December 31, 2023. The transactionwas in the form of a short-term loan. The Company received $10,000 Canadian dollars (US Dollars $7,561). This amount was owed to therelated party as of December 31, 2023 and was repaid during February 2024.

 

During June 2024, the Company entered into Sixth Amended Agreementwith Knight Therapeutics Inc., a shareholder, to modify prior Agreements. This modification consolidated outstanding loans and extendedthe maturity dates of the loans to March 31, 2026. The Company recognized interest expense of $623,355 and $1,117,459 during thesix month periods ended June 30, 2025 and 2024, respectively. The Company recognized interest expense of $253,363 and $703,301 duringthe three month periods ended June 30, 2025 and 2024, respectively. During May and June 2025, the Company repaid the balance on this amendedagreement (see Note 11).  

 

OnDecember 23, 2016, the Company entered into an agreement with Knight Therapeutics for the distribution rights of FOCUSfactor in Canada.In conjunction with this agreement, the Company is required to pay Knight a distribution fee equal to 30% of gross sales for sales achievedthrough a direct sales channel and 5% of gross sales for sales achieved through retail sales. The minimum due to Knight under this agreementis $100,000 Canadian dollars. As of both June 30, 2025 and December 31, 2024, the total outstanding balance was $123,584 Canadian dollars.In US Dollars, the total outstanding balance was $90,587 and $85,891 as of June 30, 2025 and December 31, 2024, respectively.

  

TheCompany expensed royalty of $7,788 and $41,277 for the six months ended June 30, 2025 and 2024, respectively. The Company expensed royaltyof $3,239 and $18,799 for the three months ended June 30, 2025 and 2024, respectively. At June 30, 2025 and December 31, 2024, the Companyowed Knight Therapeutics $2,368 and $2,753, respectively, in connection with a royalty distribution agreement.

 

Note 10– Accounts Payable and Accrued Liabilities

 

Asof June 30, 2025 and December 31, 2024, accounts payable and accrued liabilities consisted of the following:

 

   June 30,
2025
   December 31,
2024
 
Accrued payroll  $195,889   $76,399 
Legal fees   214,829    13,722 
Commissions   
-
    450,208 
Manufacturers   1,635,113    409,744 
Promotions   823,174    2,570,126 
Accounting fees   80,000    210,386 
Freight   154,659    149,549 
Royalties, shareholder   92,955    88,644 
Warehousing   514,872    261,046 
Sales taxes   2,878    67,488 
Payroll taxes   542,442    700,797 
Professional fees   52,600    26,200 
Insurance   
-
    12,118 
Interest   186,047    
-
 
Lender fees   375,000    
-
 
Others   89,873    155,441 
Total  $4,960,331   $5,191,868 

 

TheCompany has estimated and accrued for its sales tax liability at $3,424 and $3,703 for the parent entity as of June 30, 2025 and December31, 2024, respectively.

 

18

 

 

Note11 – Notes Payable

 

TheCompany’s notes payable at June 30, 2025 and December 31, 2024 are as follows:

 

   June 30,
2025
   December 31,
2024
 
$10,000,000 August 9, 2017 Loan  $
-
   $12,333,052 
$2,000,000 and $6,000,000 Notes   9,794,165    9,794,165 
$5,450,000 December 28, 2023 Loan   
-
    2,802,445 
$3,020,824 March 27, 2024 Loan   1,400,000    2,302,824 
Other   
-
    317,292 
$2,268,000 February 2025 Loan   567,000    
-
 
$17,500,000 May 2025 Loan   17,500,000    
-
 
    29,261,165    27,549,778 
Unamortized debt issuance cost and debt discount   (2,387,309)   (34,432)
Total   26,873,856    27,515,346 
           
Current portion, shareholder   
-
    (4,000,000)
Current portion, other   (1,894,857)   (7,725,272)
Long-term portion, shareholder   
-
    8,333,053 
Long-term portion, other  $24,978,999   $7,457,022 

 

$10,000,000August 9, 2017 Loan:

 

OnAugust 9, 2017, the Company entered into a Second Amendment to Loan Agreement (“Second Amendment”) with Knight, pursuantto which Knight agreed to loan the Company an additional $10 million.

  

TheCompany recognized interest expense of $253,363 and $703,301 for the three months ended June 30, 2025 and 2024, respectively. The Companyrecognized interest expense of $623,355 and $1,117,459 during the six months ended June 30, 2025 and 2024, respectively.

  

During June 2024, the Company entered into SixthAmended Agreement with Knight Therapeutics Inc., a shareholder, to modify prior Agreements. This modification consolidated outstandingloans and extended the maturity dates of the loans to March 31, 2026.

 

On May 29, 2025, the Company satisfied $12,713,858through a combination of (i) a $10,000,000 cash repayment, (ii) an early payment discount of $1,213,858 and (iii) a conversion of $1,500,000into equity (the “Equity Conversion”).

 

On June 11, 2025 (the “Initial ExerciseDate”), the Company issued a pre-funded common stock purchase warrant (the “Pre-Funded Warrant”) to purchase up to 428,570shares of common stock (each a “Warrant Share”), to Knight, in connection with the Equity Conversion. The Pre-Funded Warrantexpires upon the earlier of the date the Pre-Funded Warrant is exercised in full, and June 11, 2026. The aggregate exercise price of thePre-Funded Warrant, except for a nominal exercise price of $0.00001 per Warrant Share, was pre-funded to the Company on or prior to theInitial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.00001 per Warrant Share)shall be required to be paid by Knight to effect any exercise of the Pre-Funded Warrant. The Pre-Funded Warrant may be exercised, in wholeor in part, by means of a “cashless exercise.” Pursuant to Section 2(f) of the Pre-Funded Warrant, the Pre-Funded Warrantwill be automatically exercised via “cashless exercise” upon the earlier of (i) June 11, 2026, or (ii) the closing of thenext sale of equity securities of the Company. The Company relied upon the exemption from registration provided by Section 4(a)(2) ofthe Securities Act for transactions by an issuer not involving a public offering to issue the Pre-Funded Warrant. The Company valued 428,570pre-funded warrants at $899,993 resulting in a gain to the Company of $1,813,865 upon settlement of this loan.

 

Asof June 30, 2025 and December 31, 2024 the total consolidated amount outstanding on these loans, including accrued interest and royaltieswas $0 and $12,333,052, respectively.

  

$2,000,000February 10, 2022 Loan:

 

OnFebruary 10, 2022, the Company entered into a promissory note for $2,000,000 with an individual which was to be repaid with subsequentfinancing.

 

Subsequentlyand pursuant to the modification agreement entered into on June 14th, 2023, effective September 9, 2022, the promissory loanwould bear all the same characteristics as the additional $6,000,000 loan noted below.

 

19

 

 

$6,000,000March 8, 2022 Loans:

 

OnMarch 8, 2022, the Company entered into Securities Purchase Agreements with debenture holders for the Senior Subordinated Debenturesin the amount of $6,000,000 with an original maturity date of September 8, 2022 and warrants with a term of 3 years. The Senior SubordinatedDebentures were modified on June 14, 2023 in conjunction with the promissory note.

 

OnMarch 31, 2024, the Company entered into a Modification Agreement in relation to this loan, which consolidated it with the $2,000,000February 10, 2022 loan above.

 

On May 30, 2025, the Company entered into a Subordination Agreementin relation to this loan, whereby this loan becomes subordinated debt to the senior lender ($17,500,000 May and June 2025 Loan).This loan may only be repaid based on certain conditions which must be met before payment can be made. There is no maturity date on thisloan.

 

“Interest Payment Conditions” meanswith respect to any payment of interest on any Sanders Note, the satisfaction of the following conditions:

 

(a) as of the date of any such interest paymentand immediately after giving effect thereto, no Default or Event of Default has occurred and is continuing;

 

(b) Liquidity (prior to and after giving effectto such payment) shall not be less than $2,000,000;

 

(c) the Fixed Charge Coverage Ratio of the Borrowerand its Subsidiaries for the period of 12 fiscal months of the Borrower and its Subsidiaries most recently ended prior to such payment(and, for the avoidance of doubt, without giving effect to such payment for purposes of determining Consolidated Net Interest Expense),shall be not less than 1.20 to 1.00; and

 

(d) the Administrative Agent shall have receiveda certificate of an Authorized Officer of the Borrower certifying as to compliance with the preceding clauses and demonstrating (in reasonabledetail) the calculation required thereby.

 

“Principal Payment Conditions” meanswith respect to any payment or prepayment of principal on any Sanders Note, the satisfaction of the following conditions:

 

(a) as of the date of any such principal paymentand immediately after giving effect thereto, no Default or Event of Default has occurred and is continuing;

 

(b) Liquidity (prior to and after giving effectto such payment) shall not be less than $4,000,000;

 

(c) the Fixed Charge Coverage Ratio of the Borrowerand its Subsidiaries for the period of 12 fiscal months of the Borrower and its Subsidiaries most recently ended prior to such payment(and, for the avoidance of doubt, without giving effect to such payment for purposes of determining Consolidated Net Interest Expense),shall be not less than 1.20 to 1.00;

 

(d) the Consolidated Senior Net Leverage Ratioof the Borrower and its Subsidiaries as of the end of such fiscal quarter of the Borrower ending on or most recently preceding the dateof such payment or prepayment was less than 2.75 to 1.00;

 

(e) such payment or prepayment is made using onlyNet Cash Proceeds of an Equity Issuance which are not required to be applied as a mandatory prepayment pursuant to Section 2.5(c)(v) inan amount not to exceed fifty percent (50%) of such Net Cash Proceeds; and

 

(f) the Administrative Agent shall have receiveda certificate of an Authorized Officer of the Borrower certifying as to compliance with the preceding clauses and demonstrating (in reasonabledetail) the calculation required thereby.

 

On April 28, 2025, the Company entered into Assignment,Assumption and Release Agreement with the holder to release Jack Ross (CEO of the Company) from the obligation to personally grant warrantsstruck at $0.01 penny per share, covering 10% of his stock to the lender for non-payment of principal amount plus loan renegotiation feesby December 31, 2024. The Company issued 441,178 shares valued at $847,062 to the lender for releasing Jack Ross (CEO) from this obligation.

 

20

 

 

$5,450,000December 28, 2023 Loan:

 

OnDecember 28, 2023, the Company entered into a confidential settlement agreement and mutual general release with a former supplier. Theloan bears interest at 5% per annum and is payable in full with the last payment. This settlement resulted in a gain to the Company of$2,235,986 and is reflected as a reduction of cost of sales (See Note 13).

 

During 2025 and 2024, the Company made payments of $2,622,201 and $2,000,000,respectively toward this loan. During June 2025, the supplier agreed to a Payoff Letter re: Settlement Agreement, resulting in a lesserprepay amount resulting in a gain to the Company of $180,245.

 

Theoutstanding loan balance at June 30, 2025 and December 31, 2024 was $0 and $2,802,445, respectively.

 

$3,020,824March 27, 2024 Loan:

 

OnMarch 27, 2024, the Company entered into a confidential settlement agreement and mutual general release with a supplier.

 

During2025 and 2024, the Company made payments of $760,412 and $700,000 toward this loan. During June 2025, the supplier agreed to a PayoffLetter re: Settlement Agreement, resulting in a lesser prepay amount, resulting in a gain to the Company of $160,412. The outstandingloan balance at June 30, 2025 and December 31, 2024 was $1,400,000 and $2,320,824, respectively. This was subsequently repaid in full.

 

TheCompany is required to make future payments as follows:

 

2025  $1,400,000 

 

$418,100May 1, 2024 Loan:

 

OnMay 1, 2024, the Company entered into a loan agreement of $418,100 with Shopify Capital Inc. for an advancement of working capital fromits online processing account. The Company received $370,000 from Shopify Capital Inc. and $48,100 was an original issue discount. Theloan bears a repayment rate of 25% of daily sales.

 

TheCompany recognized amortization of original issue discount of $21,989 and $32,297 which is included in interest expense in the statementof income during the three and six months ended June 30, 2025, respectively.

 

Theoutstanding loan balance at June 30, 2025 and December 31, 2024 was $0 and $280,732, respectively. 

 

$118,650May 22, 2024 Loan:

 

OnMay 22, 2024, the Company entered into a loan agreement of $118,650 with Shopify Capital Inc. for an advancement of working capitalfrom its online processing account. The Company received $105,000 from Shopify Capital Inc. and $13,650 was an original issuediscount. The loan bears a repayment rate of 25% of daily sales.

 

Thepayment of such amounts is secured by a security interest in certain assets, undertakings and property pursuant to the Security Agreement,which will be released upon receipt of total payments of $118,650.

 

TheCompany recognized amortization of original issue discount of $2,135 and $1,464, which is included in interest expense in the statementof income during the six months ended June 30, 2025 and 2024, respectively. The outstanding loan balance at June 30, 2025 and December31, 2024 was $0 and $16,425, net of unamortized original issue discount of $2,135, respectively.

 

21

 

 

$800,000December 5, 2024 Loan:

 

OnDecember 5, 2024, the Company entered into a cash advance agreement of $800,000 with Cedar Advance LLC for an advancement of workingcapital. The Company received $760,000 and recorded $40,000 as interest expense. The loan bears a repayment rate of $41,100 perweek. In conjunction with the advance, the Company issued 18,000 shares of common stock to the consultant who facilitated thefacility and thus recognized $97,920 as interest expense.

 

TheCompany recognized total interest expense of $136,000 during the year ended December 31, 2024. The outstanding loan balance at December31, 2024 was $0.

 

$2,268,000February 2025 Loan:

 

OnJanuary 29, 2025, the Company entered into a cash advance agreement of $2,268,000 with Cedar Advance LLC for an advancement of workingcapital. The Company received $1,496,250 and recorded $771,750 as original issue discount. The loan bears a repayment rateof $81,000 per week with a total payment of $2,268,000. In conjunction with the advance, the Company issued 30,360 sharesof common stock to the consultant who facilitated the facility and thus recognized $117,648 as financing cost.

 

TheCompany recognized total interest expense of $422,857 and $817,255 and during the three and six months ended June 30, 2025, respectively.The outstanding loan balance at June 30, 2025 was $494,857, net of unamortized debt discount and financing costs of $72,143.

 

$17,500,000May 2025 Loan:

 

On May 30, 2025, Synergy CHC Corp. (the “Company”)entered into a term loan credit agreement (the “Credit Agreement”) with ACP Agency, LLC (“ACP”). The Credit Agreementconsists of a $15.0 million term loan (the “Term Loan”), up to $2.5 million in a committed delayed draw facility (the “DelayedDraw Facility”), and up to $2.5 million in an uncommitted term loan incremental facility (the “Incremental Facility”),which facilities are secured by all of the assets of the Company and certain of its subsidiaries; including, without limitation, a pledgeof the Company’s equity interests in its subsidiaries and their respective rights to intellectual property. Further, the obligationsof the Company under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries. The proceeds of the Term Loanare to be used to repay existing indebtedness of the Company, pay related fees and transaction costs, and provide working capital to theCompany. The proceeds of the Delayed Draw Facility are to be used to pay off all indebtedness owed by the Company pursuant to certainsettlement agreements. All capitalized words used but not defined herein have the meanings assigned in the Credit Agreement.

 

The Credit Agreement has customary representations,warranties and covenants including restrictions on indebtedness, liens, restricted payments and dividends, investments, asset sales andsimilar covenants and contains customary events of default. The Credit Agreement also contains covenants requiring the Company and itssubsidiaries to maintain a maximum (x) consolidated senior net leverage ratio of (i) 3.25:1.00 for the quarter ending September 30, 2025,(ii) 3.25:1.00 for the quarter ending December 31, 2025, (iii) 3.00:1.00 for the quarter ending March 31, 2026, (iv) 2.75:1.00 for thequarter ending June 30, 2026, (v) 2.75:1.00 for the quarter ending September 30, 2026, and (vi) 2.50:1.00 for the quarter ending December31, 2026 and each fiscal quarter ended thereafter and (y) a fixed charge coverage ratio of 1.20 for the quarter ending September 30, 2025and each fiscal quarter ended thereafter.

 

22

 

 

Of the Term Loan, $175,000 is subject to repaymenton each of January 1, 2026, April 1, 2026, July 1, 2026 and October 1, 2026 and the remaining balance is to be repaid in the amount of$350,000 beginning January 1, 2027 and the first day of each quarter thereafter. The Term Loan bears interest at a rate equal to the TermSOFR rate plus 8.50%. The Delayed Draw Facility and Incremental Facility, if applicable, shall bear interest following any advance ofproceed thereunder, at a rate of either (x) (i) Term SOFR rate plus (ii) 8.5%, or (y) (i) a reference rate equal to the greater of (a)6.0% per annum, (b) the federal funds rate plus 0.50% per annum, (c) the Term SOFR rate plus 1% per annum, and (d) the rate last quotedby The Wall Street Journal as the “Prime Rate” in the United States, plus (ii) 7.50%.

 

The Company received $15,000,000 in May 2025 on the initial draw and$2,500,000 in June 2025 on a delayed draw. The proceeds of the loan were used to pay out existing debt. The Company recorded $2,355,914as original debt discount. The Company recognized $40,748 as amortization during the period. The unamortized balance amounts to $2,315,166at June 30, 2025.

 

Thenote bears interest at Term SOFR rate, plus 8.5%, currently 12.83% per annum, and matures on May 30, 2029.

 

TheCompany recognized interest expense of $186,047 during the three months ended June 30, 2025.

 

TheCompany is required to make future payments as follows:

 

2025  $- 
2026  $700,000 
2027  $1,400,000 
2028  $1,400,000 
2029  $14,000,000 

 

Note 12 – Stockholders’ Deficit

 

Thetotal number of shares of all classes of capital stock which the Company is authorized to issue is 300,000,000 shares of common stockwith $0.00001 par value.

 

During2025 and 2024 the Company issued 30,360 and 18,000 shares, respectively, to a consultant who facilitated a cash advance facility(Note 11).

 

During 2025, the Company issued 428,570 pre-fundedwarrants to a Knight as a partial settlement of debt. These warrants were fully exercised during the six months ended June 30, 2025.

 

During 2025, the Company issued 441,178 shares valued at $847,062 inconjunction with an assignment, assumption and release agreement with a note holder (see Note 11).

 

Asof June 30, 2025 and December 31, 2024, there were 9,621,926 and 8,721,818 shares issued, respectively, and 9,441,853 and 8,541,745shares outstanding, respectively.

 

23

 

 

Note 13– Commitments and Contingencies

 

Litigation:

 

Fromtime to time the Company may become a party to litigation in the normal course of business. Management believes that there are no currentlegal matters that would have a material effect on the Company’s financial position or results of operations.

 

Note14 – Stock Options and Warrants

 

Thefollowing table summarizes the options outstanding, option exercisability and the related prices for the shares of the Company’scommon stock issued to employees and consultants under a stock option plan at June 30, 2025:

 

    Options Outstanding   Options Exercisable 
Exercise Prices ($)   Number
Outstanding
   Weighted
Average
Remaining
Contractual
Life
(Years)
   Weighted
Average
Exercise
Price ($)
   Number
Exercisable
   Weighted
Average
Exercise
Price ($)
 
$2.98-7.74    252,102    0.46   $6.15    252,102   $6.15 

 

Thestock option activity for the six months ended June 30, 2025 is as follows:

 

   Options
Outstanding
   Weighted Average
Exercise Price
 
Outstanding at December 31, 2024   252,102   $6.15 
Granted   -    - 
Exercised   -    - 
Expired or canceled   -    - 
Outstanding at June 30, 2025   252,102   $6.15 

 

Stock-basedcompensation expense related to vested options was $0 during both the six months ended June 30, 2025 and 2024. Stock options outstandingas of June 30, 2025, as disclosed in the above table, have an intrinsic value of $0.

 

The following table summarizes the changes in warrants outstandingand the related prices for the shares of the Company’s common stock issued at June 30, 2025:

 

    Warrants Outstanding   Warrants Exercisable 
Exercise Price ($)   Number
Outstanding
   Weighted
Average
Remaining
Contractual
Life
(Years)
   Weighted
Average
Exercise
Price ($)
   Number
Exercisable
   Weighted
Average
Exercise
Price ($)
 
$11.70    103,500    3.57   $11.70    103,500   $11.70 

 

24

 

 

Thewarrant activity for the six months ended June 30, 2025 is as follows:

 

   Warrants
Outstanding
   Weighted Average
Exercise Price
 
Outstanding at December 31, 2024   103,500   $11.70 
Granted   428,570    0.00001 
Exercised   (428,570)   (0.00001)
Expired or canceled   -    - 
Outstanding at June 30, 2025   103,500   $11.70 

 

Stockwarrants outstanding as of June 30, 2025, as disclosed in the above table, have an intrinsic value of $0.

 

During June 2025, the Company issued 428,570 warrants valued at $899,993to settle a loan payable to a shareholder. The Company determined the value of the warrants using the Black-Scholes fair value option-pricingmodel with the following weighted average assumptions: estimated fair value of the Company’s common stock of $2.10, risk-free interestrate of 4.30%, volatility of 97%, expected term of 0.1 years and dividend yield of 0%.

 

Note15 – Segments 

 

Segmentidentification and selection is consistent with the management structure used by the Company’s chief executive officer who is theChief Operating Decision Maker (CODM) to evaluate performance and make decisions regarding resource allocation, as well as the materialityof financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting,the Company has one operating segment. The Company derives its revenue from the sale of nutraceuticals. The accounting policiesof the segment are the same as those described in the summary of significant accounting policies. The chief operating decision makerassesses performance for the segment and decides how to allocate resources based on net income that also is reported on the income statementas consolidated net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. Significantsegment expenses include retailer promotions, freight and fulfillment, marketing and salaries. The Company’s CODM reviews financialinformation presented and decides how to allocate resources based on net income. The Company does have any intra-entity sales or transfers.The Company’s CODM does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviewsoperating results on an aggregated basis.

 

Netsales attributed to customers in the United States and foreign countries for the three months ended June 30, 2025 and 2024 were as follows:

 

   June 30,
2025
   June 30,
2024
 
United States  $7,954,326   $6,705,486 
Foreign countries   180,670    1,319,354 
   $8,134,996   $8,024,840 

 

Foreigncountry sales primarily consist of sales in Canada. 

 

TheCompany’s net sales by product group for the three months ended June 30, 2025 and 2024 were as follows:

 

   June 30,
2025
   June 30,
2024
 
Nutraceuticals  $6,734,996   $8,024,840 
License Revenue   1,400,000    - 
   $8,134,996   $8,024,840 

 

25

 

 

TheCompany’s net sales by major sales channel for the three months ended June 30, 2025 and 2024 were as follows:

 

   June 30,
2025
   June 30,
2024
 
Online  $2,074,439   $979,540 
Retail   6,060,557    7,045,300 
   $8,134,996   $8,024,840 

  

TheCompany’s significant segment expenses for the three months ended June 30, 2025 and 2024 were as follows:

 

   June 30,
2025
   June 30,
2024
 
Retailer promotions  $1,160,615   $1,191,671 
Freight and fulfillment   396,436    501,982 
Online marketing   931,994    1,005,771 
Salaries and benefits, marketing   377,785    283,631 
Other selling and marketing   195,381    317,164 
IT expenses   163,608    158,035 
Salaries and benefits, non-marketing   591,170    440,970 
Professional fees   432,866    (119,829)
Travel   71,895    55,064 
Other general and administrative expenses   259,786    124,565 
Amortization   33,334    33,334 
   $4,614,870   $3,992,358 

 

Netsales attributed to customers in the United States and foreign countries for the six months ended June 30, 2025 and 2024 were as follows:

 

    June 30,
2025
    June 30,
2024
 
United States   $ 15,409,050     $ 14,984,092  
Foreign countries     896,480       2,452,611  
    $ 16,305,530     $ 17,436,703  

 

Foreigncountry sales primarily consist of sales in Canada. 

 

TheCompany’s net sales by product group for the six months ended June 30, 2025 and 2024 were as follows:

 

   June 30,
2025
   June 30,
2024
 
Nutraceuticals  $13,405,530   $17,436,703 
License Revenue   2,900,000    
-
 
   $16,305,530   $17,436,703 

 

26

 

 

TheCompany’s net sales by major sales channel for the six months ended June 30, 2025 and 2024 were as follows:

 

   June 30,
2025
   June 30,
2024
 
Online  $4,836,284   $2,150,177 
Retail   11,469,246    15,286,526 
   $16,305,530   $17,436,703 

  

TheCompany’s significant segment expenses for the six months ended June 30, 2025 and 2024 were as follows:

 

   June 30,
2025
   June 30,
2024
 
Retailer promotions  $2,100,068   $2,731,307 
Freight and fulfillment   894,184    1,098,279 
Online marketing   1,863,821    1,850,009 
Salaries and benefits, marketing   705,959    678,469 
Other selling and marketing   374,450    526,831 
IT expenses   304,184    295,899 
Salaries and benefits, non-marketing   1,159,163    1,037,565 
Professional fees   596,634    81,347 
Travel   227,015    133,800 
Other general and administrative expenses   539,043    458,580 
Amortization   66,667    66,667 
   $8,831,188   $8,958,753 

 

Long-livedassets (net) attributable to operations in the United States and foreign countries as of June 30, 2025 and December 31, 2024 were asfollows:

 

    June 30, 2025     December 31,
2024
 
United States   $ 216,667     $ 283,333  
Foreign countries     -       -  
    $ 216,667     $ 283,333  

 

Note16 – Subsequent Events 

 

Managementevaluated all activities of the Company through the issuance date of the Company’s unaudited condensed consolidated financial statementsand concluded that except as noted below, no subsequent events have occurred that would require adjustment or disclosure into the unauditedcondensed consolidated financial statements.

 

Subsequent to June 30, 2025, the Company has repaid$1,400,000 of principal on the March 27, 2024 loan, $416,614 of principal and $69,386 of interest on the February 2025 loan, $92,942 ofinterest on the March 8, 2022 loan and $379,371 of interest on the May 2025 loan.

 

27

 

 

Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 

 

Referencesin this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to SynergyCHC Corp. References to our “management” or our “management team” refer to our officers and directors. The followingdiscussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensedconsolidated financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained inthe discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Our actual resultsmay differ significantly from the results, expectations and plans discussed in these forward-looking statements.

 

SpecialNote Regarding Forward-Looking Statements

 

ThisQuarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21Eof the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materiallyfrom those expected and projected. All statements, other than statements of historical fact included in this Form 10-Q including,without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations”regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-lookingstatements. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,”“expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,”“predict,” “project,” “should,” “would” and variations thereof and similar words andexpressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or futureperformance, but reflect management’s current beliefs, based on information currently available. A number of factors could causeactual events, performance or results to differ materially from the events, performance and results discussed in the forward-lookingstatements. For information identifying important factors that could cause actual results to differ materially from those anticipatedin the forward-looking statements, please refer to the Risk Factors section of our final prospectus for our initial public offering filedwith the SEC on October 23, 2024 (the “Prospectus”) and the “Risk Factors” section of this report. Our securitiesfilings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securitieslaw, we disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information,future events or otherwise.

 

Thefollowing discussion and analysis of our financial condition and results of operations should be read in conjunction with the unauditedcondensed consolidated financial statements and the notes thereto contained elsewhere in this report. Certain information contained inthe discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

 

Overview

 

Weare a provider of consumer health care, beauty, and lifestyle products. Our current brand portfolio consists of two core brands: FOCUSfactor,a clinically-tested brain health supplement (this study was performed independently and is not related to any FDA-approved InvestigationalNew Drug application) that has been shown to improve memory, concentration and focus and Flat Tummy, a lifestyle brand that providesa suite of nutritional products to help women achieve their weight management goals.

 

Ourmanagement’s discussion and analysis of our financial condition and results of operations are only based on our current businessand should be read in conjunction with our unaudited interim condensed consolidated financial statements and audited consolidated financialstatements and accompanying notes thereto included elsewhere in this Quarterly Report. Key factors affecting our results of operationsinclude revenues, cost of revenue, operating expenses and income and taxation.

 

28

 

 

Non-GAAPFinancial Measures

 

Wecurrently focus on EBITDA to evaluate our business relationships and our resulting operating performance and financial position. EBITDAis defined as net income plus interest expense, income tax expense, depreciation and amortization.

 

Webelieve that EBITDA, viewed in addition to, and not in lieu of, our reported results in accordance with accounting principles generallyaccepted in the United States (“U.S. GAAP”), provides useful information to investors.

 

   Three Months
Ended
June 30, 2025
   Three Months
Ended
June 30, 2024
 
   (Unaudited)   (Unaudited) 
Net income  $1,473,237   $655,186 
Interest income   (379)   (374)
Interest expense   2,107,714    745,528 
Income tax expense   190,107    179,382 
Depreciation and amortization   33,334    33,334 
EBITDA  $3,804,013   $1,613,056 

 

   Six Months
Ended
June 30, 2025
   Six Months
Ended
June 30, 2024
 
   (Unaudited)   (Unaudited) 
Net income  $2,349,501   $1,235,716 
Interest income   (14,261)   (761)
Interest expense   3,203,083    1,855,508 
Income tax expense   178,647    306,571 
Depreciation and amortization   66,667    66,667 
EBITDA  $5,783,637   $3,463,701 

 

EBITDAis considered non-GAAP financial measures. EBITDA represents earnings before interest, taxes, depreciation and amortization. Our definitionof EBITDA might not be comparable to similarly titled measures reported by other companies.

 

Resultsof Operations for the Three Months Ended June 30, 2025 and June 30, 2024

 

Duringboth the three months ended June 30, 2025 and 2024, we focused on developing our currently owned brands into new markets and byproduct extensions. Our objective is to grow our two targeted verticals (Nutraceuticals and Ready To Drinks (RTDs)) to provide a balancedand synergistic portfolio that drives consumer demand via multiple channels. Our Nutraceuticals vertical consists of FOCUSfactor, includingRTDs, and Flat Tummy consumables.

 

Revenue

 

For the three monthsended June 30, 2025, we had revenue of $6,734,996 from sales of our products and $1,400,000 from a license agreement, as compared torevenue of $8,024,840 for the three months ended June 30, 2024. The revenue is comprised of the following categories:

 

    June 30,
2025
    June 30,
2024
 
Nutraceuticals   $ 6,734,996     $ 8,024,840  
License Revenue     1,400,000       -  
    $ 8,134,996     $ 8,024,840  

 

29

 

 

We had a decrease in Nutraceuticals revenue in the three monthsended June 30, 2025 as compared to the three months ended June 30, 2024 due to a new product sell-in to one customer in 2024 thatdid not repeat in 2025. We also had revenue from a license agreement to expand into selected foreign territories.

 

Costof Revenue

 

Forthe three months ended June 30, 2025, our cost of revenue was $1,896,391. Our cost of revenue for the three months ended June30, 2024, was $2,448,890. The decrease in cost of sales was primarily due to the decrease in revenue.

 

GrossProfit

 

Gross profit was $6,238,605, or 77% of revenue, for the three monthsended June 30, 2025, as compared to gross profit of $5,575,950, or 69% of revenue, for the same period in 2024, an increase of $662,665,or 12%. The increase in gross profit is directly related to the license revenue.

 

OperatingExpenses

 

Sellingand Marketing Expenses

 

Forthe three months ended June 30, 2025, our selling and marketing expenses were $3,062,211 as compared to $3,055,186 for the three monthsended June 30, 2024, which is an immaterial increase.

 

Generaland Administrative Expenses

 

Forthe three months ended June 30, 2025, our general and administrative expenses were $1,519,325. For the three months ended June 30,2024, our general and administrative expenses were $903,838. The increase is primarily due to public market expenses.

 

Depreciationand Amortization Expenses

 

For the three months ended June 30, 2025, our depreciation andamortization expenses were $33,334 as compared to $33,334 for the three months ended June 30, 2024.

 

OtherIncome and Expenses

 

Forthe three months ended June 30, 2025 and 2024 we had other income and expense items as follows:

 

   Three months
ended
June 30,
2025
   Three months
ended
June 30,
2024
 
Interest expense  $2,107,714   $745,528 
Interest income   (379)   (374)
Gain on settlement of loans   (2,154,522)   - 
Remeasurement loss on translation of foreign subsidiary   7,578    3,870 
Total other (income) expense  $(39,609)  $749,024 

 

For the three months ended June 30, 2025, we had interest expenseof $2,107,714 as compared to $745,528 for the three months ended June 30, 2024. The increase is primarily due to the advance, sharesissued related to the modification of notes payable and new May 2025 loan.

 

30

 

 

NetIncome

 

For the three months ended June 30, 2025, our net income was $1,473,237as compared to a net income of $655,186 for the three months ended June 30, 2024 due to a gain on settlement of loans.

 

Resultsof Operations for the Six Months Ended June 30, 2025 and June 30, 2024

 

Duringboth the six months ended June 30, 2025 and 2024, we focused on developing our currently owned brands into new markets and by productextensions. Our objective is to grow our two targeted verticals (Nutraceuticals and Ready To Drinks (RTDs)) to provide a balanced andsynergistic portfolio that drives consumer demand via multiple channels. Our Nutraceuticals vertical consists of FOCUSfactor, includingRTDs, and Flat Tummy consumables.

 

Revenue

 

For the six months ended June 30, 2025, we had revenue of $13,405,530from sales of our products and $2,900,000 from a license agreement, as compared to revenue of $17,436,703 for the six months endedJune 30, 2024. The revenue is comprised of the following categories:

 

   June 30,
2025
   June 30,
2024
 
Nutraceuticals  $13,405,530   $17,436,703 
License Revenue   2,900,000    - 
   $16,305,530   $17,436,703 

 

We had a decrease in Nutraceuticalsrevenue in the six months ended June 30, 2025 as compared to the six months ended June 30, 2024 due to a new product sell-into one customer in 2024 that did not repeat in 2025. We also had revenue from a license agreement to expand into selected foreign territories.

 

Costof Revenue

 

Forthe six months ended June 30, 2025, our cost of revenue was $3,902,904. Our cost of revenue for the six months ended June 30,2024, was $5,086,029. The decrease in cost of sales was primarily due to the decrease in revenue.

 

GrossProfit

 

Grossprofit was $12,402,626, or 76% of revenue, for the six months ended June 30, 2025, as compared to gross profit of $12,350,674, or71% of revenue, for the same period in 2024, an increase of $51,952, or 0.4%. The increase in gross profit is related to the licenserevenue.

 

OperatingExpenses

 

Sellingand Marketing Expenses

 

Forthe six months ended June 30, 2025, our selling and marketing expenses were $5,938,482 as compared to $6,639,863 for the six monthsended June 30, 2024, which is primarily due to lower revenue and an improved management of promotions in 2025.

 

Generaland Administrative Expenses

 

Forthe six months ended June 30, 2025, our general and administrative expenses were $2,826,039. For the six months ended June 30, 2024,our general and administrative expenses were $2,252,223. The increase is primarily public market expenses.

 

31

 

 

Depreciationand Amortization Expenses

 

Forthe six months ended June 30, 2025, our depreciation and amortization expenses were $66,667 as compared to $66,667 for the six monthsended June 30, 2024.

 

OtherIncome and Expenses

 

Forthe six months ended June 30, 2025 and 2024 we had other income and expense items as follows:

 

   Six months
ended
June 30,
2025
   Six months
ended
June 30,
2024
 
         
Interest expense  $3,203,083   $1,855,508 
Interest income   (14,261)   (761)
Gain on settlement of loans   (2,154,522)   - 
Remeasurement loss (gain) on translation of foreign subsidiary   8,990    (5,113)
Total other expense  $1,043,290   $1,849,634 

 

For the six months ended June 30, 2025, we had interest expense of$3,203,083 as compared to $1,855,508 for the six months ended June 30, 2024. The increase is primarily due to an advance taken in2025, shares issued related to the modification of notes payable and new May 2025 loan.

 

NetIncome

 

For the six months ended June 30, 2025, our net income was $2,349,501as compared to a net income of $1,235,716 for the six months ended June 30, 2024 due to lowering operating expenses and gain on loansettlements.

 

Liquidityand Capital Resources

 

Overview

 

Asof June 30, 2025, we had $1,458,561 cash on hand and restricted cash of $100,000 which is held for credit card collateral.

 

CashFlows from Operating Activities 

 

For the six months endedJune 30, 2025, net cash used in operating activities was $899,731 compared to net cash used in operating activities of $1,140,005 forthe six months ended June 30, 2024. This decrease in net cash used by operating activities for the six months ended June 30,2025 is detailed in the table below.

 

32

 

 

For the six months ended June 30, 2025, net cash used in operatingactivities of $899,731 consisted of our net income of $2,349,501 adjusted by:

 

Amortization of debt discount and debt issuance cost   892,435 
Depreciation and amortization   66,667 
Stock issued for modification of notes payable   847,062 
Foreign currency transaction gain   (9,068)
Remeasurement loss on translation of foreign subsidiary   8,990 
Gain on settlement of debt   (2,154,522)
Accounts receivable   (1,748,852)
Other receivables   (25,457)
Loan receivable, related party   (52,824)
Inventory   (647,606)
Prepaid expenses   283,848 
Prepaid expense, related party   (488,379)
Income taxes payable   23,495 
Contract liabilities   (19,365)
Accounts payable and accrued liabilities   (610,770)
Accounts payable, shareholder   385,114 

  

For the six months ended June 30, 2024, net cash used in operatingactivities of $1,140,004 consisted of our net income of $1,235,716 adjusted by:

 

Depreciation and amortization  $66,667 
Stock based compensation expense   4,611 
Foreign currency transaction loss   23,345 
Remeasurement gain on translation of foreign subsidiary   (5,113)
Non cash implied interest   4,799 
Accounts receivable   (1,161,992)
Loan receivable, related party   35,449 
Inventory   1,805,950 
Prepaid expenses   (276,818)
Prepaid expense, related party   (326,682)
Income taxes payable   262,374 
Contract liabilities   (2,949)
Accounts payable and accrued liabilities   (2,804,381)
Accounts payable, shareholder   (980)

 

33

 

 

CashFlows from Investing Activities

 

Forthe six months ended June 30, 2025 and 2024, we used net cash of $0 in investing activities.

 

CashFlows from Financing Activities

 

For the six months ended June 30, 2025, net cash provided by financingactivities was $1,632,433 compared to net cash provided by financing activities of $407,391 for the six months ended June 30, 2024.The increase was attributable to new loans.

 

Financingactivities during the six months ended June 30, 2025 and 2024:

 

   Six months
ended
June 30,
2025
   Six months
ended
June 30,
2024
 
Advances from related party  $135,000   $1,509,226 
Repayment of notes payable, related party   (135,000)   (84,500)
Proceeds from notes payable   18,996,250    600,000 
Payment of loan financing fees   (1,980,914)   - 
Repayment of notes payable, shareholder   (10,000,000)   - 
Repayment of notes payable   (5,382,903)   (1,617,335)

 

KeyNear-Term Initiatives

 

Weintend to organically grow our current product lines by developing and launching new products and expanding into new markets. Specifically,for FOCUSfactor, we are working on increased distribution for our recently launched ready-to-drink beverage. Lastly, we intend to growfurther through additional strategic acquisitions and we continue to evaluate opportunities and candidates that we believe fit well withour brand portfolio.

 

Off-BalanceSheet Arrangements

 

Duringthe six months ended June 30, 2025, and during the year ended December 31, 2024, we had no off-balance sheet arrangements.

 

Inflation

 

Theeffect of inflation on our operating results was not significant in the six months ended June 30, 2025 or 2024.

 

CriticalAccounting Estimates

 

Thepreparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect thereported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue andexpenses during the reported periods. The more critical accounting estimates include estimates related to revenue recognition and accountsreceivable allowances. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions thatare significant to understanding our results, which are described in Note 2 to our unaudited condensed consolidated financial statementsappearing elsewhere in this report.

 

RecentAccounting Pronouncements

 

Note2 to our unaudited condensed consolidated financial statements appearing elsewhere in this report includes Recent Accounting Pronouncements.

 

34

 

 

Item3. Quantitative and Qualitative Disclosures About Market Risk

 

Asa smaller reporting company, we have elected not to provide the disclosure required by this item.

 

Item4. Controls and Procedures

 

Evaluationof Disclosure Controls and Procedures

 

Management,under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, have conducted an evaluationof the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)under the Exchange Act). Disclosure controls and procedures are designed to ensure that information required to be disclosed by a companyin the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periodsspecified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and proceduresdesigned to ensure that information required to be disclosed by a company in the reports that it files or submits under the ExchangeAct is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriateto allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and our Chief FinancialOfficer, concluded that as of the end of the period covered by this Quarterly Report, (i) the Company’s disclosure controls andprocedures were not effective to ensure that material information relating to the Company is recorded, processed, summarized, and reportedwithin the time periods specified in the rules and forms of the Securities and Exchange Commission (the “Commission”), and(ii) the Company’s controls and procedures have not been designed to ensure that information required to be disclosed by the Companyin the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to theCompany’s management, including its principal executive and principal financial officers, or persons performing similar functions,as appropriate to allow timely decisions regarding required disclosure.

 

Changesin Internal Control Over Financial Reporting

 

Therehas been no change in our internal control over financial reporting, as defined in Rules 13a-15(f) of the Exchange Act, during the quarterended June 30, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financialreporting.

 

35

 

 

PARTII—OTHER INFORMATION

 

Item1. Legal Proceedings.

 

Weare not party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incidentto the ordinary course of business. The outcome of litigation is inherently uncertain, and there can be no assurances that favorableoutcomes will be obtained. In addition, regardless of the outcome, such proceedings or claims can have an adverse impact on us, whichmay be material because of defense and settlement costs, diversion of resources and other factors.

 

Item1A. Risk Factors.

 

Asa smaller reporting company under Rule 12b-2 of the Exchange Act, we are not required to include risk factors in this Quarterly Report.However, as of the date of this Quarterly Report, there have been no material changes with respect to those risk factors previously disclosedin the “Risk Factors” section of the Prospectus. Any of these factors could result in a significant or material adverse effecton our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterialmay also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factorsfrom time to time in our future filings with the SEC.

 

Item2. Unregistered Sales of Equity Securities and Use of Proceeds

 

(a)None.

 

(b)None.

 

(c)None.

 

Item3. Defaults Upon Senior Securities.

 

None.

 

Item4. Mine Safety Disclosures.

 

Notapplicable.

 

Item5. Other Information.

 

(a)None.

 

(b)None.

 

(c)During the quarter ended June 30, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement”or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

36

 

 

Item6. Exhibits

 

Thefollowing exhibits are filed as part of, or incorporated by reference into, this Quarterly Report.

 

No.   Description of Exhibit
2.1   Agreement and Plan of Merger, dated April 7, 2014, by and among Oro Capital Corporation, Synergy Merger Sub, Inc. and Synergy Strips Corp. (incorporated by reference to Exhibit 2.1 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. with the SEC on June 28, 2024)
2.2   Asset Purchase Agreement, dated January 16, 2015, by and among Synergy Strips Corp.; Factor Nutrition Labs, LLC; Vita Partners, LLC, RPR Partners, LLC, and Thor Associates, Inc. (incorporated by reference to Exhibit 2.2 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. with the SEC on June 28, 2024)
2.3   Asset Purchase Agreement, dated June 26, 2015, by and between Neuragen Corp. and Knight Therapeutics, Inc. (incorporated by reference to Exhibit 2.3 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. with the SEC on June 28, 2024)
3.1   Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. with the SEC on September 16, 2024)
3.2   Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. with the SEC on June 18, 2025)
3.3   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. with the SEC on June 28, 2024)
4.1   Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. with the SEC on June 12, 2025)
10.1 ¥   Credit Agreement, dated as of May 30, 2025, by and among Synergy CHC Corp. as Borrower, each subsidiary of the Borrower listed as a Guarantor therein, the lenders from time-to-time party thereto as Lenders and ACP Agency, LLC, as Collateral Agent and Administrative Agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. with the SEC on June 4, 2025)
10.2   Amendment to Synergy CHC Corp. 2024 Equity Incentive Plan(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. with the SEC on June 18, 2025)
31.1*   Rule 13a-14(a) Certification by Principal Executive Officer
31.2*   Rule 13a-14(a) Certification by Principal Financial and Accounting Officer
32.1**   Section 1350 Certification of Principal Executive Officer
32.2**   Section 1350 Certification of Principal Financial and Accounting Officer
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*   Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101)

 

* Filed with this Report.
** Furnished with this Report.

¥Certain schedules and exhibits to this agreement have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC on request.

 

37

 

 

SIGNATURES

 

Pursuantto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf bythe undersigned thereunto duly authorized.

 

  SYNERGY CHC CORP.
     
Date: August 14, 2025 By: /s/ Jack Ross
  Name:  Jack Ross
  Title: Chief Executive Officer and Chairman
    (Principal Executive Officer)

 

 

38

 

 

http://fasb.org/srt/2025#ChiefExecutiveOfficerMember http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 0001562733 false Q2 --12-31 0001562733 2025-01-01 2025-06-30 0001562733 2025-08-12 0001562733 2025-06-30 0001562733 2024-12-31 0001562733 us-gaap:RelatedPartyMember 2025-06-30 0001562733 us-gaap:RelatedPartyMember 2024-12-31 0001562733 snyr:ProductSalesMember 2025-04-01 2025-06-30 0001562733 snyr:ProductSalesMember 2024-04-01 2024-06-30 0001562733 snyr:ProductSalesMember 2025-01-01 2025-06-30 0001562733 snyr:ProductSalesMember 2024-01-01 2024-06-30 0001562733 us-gaap:LicenseMember 2025-04-01 2025-06-30 0001562733 us-gaap:LicenseMember 2024-04-01 2024-06-30 0001562733 us-gaap:LicenseMember 2025-01-01 2025-06-30 0001562733 us-gaap:LicenseMember 2024-01-01 2024-06-30 0001562733 2025-04-01 2025-06-30 0001562733 2024-04-01 2024-06-30 0001562733 2024-01-01 2024-06-30 0001562733 us-gaap:CommonStockMember 2023-12-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001562733 us-gaap:TreasuryStockCommonMember 2023-12-31 0001562733 us-gaap:RetainedEarningsMember 2023-12-31 0001562733 2023-12-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001562733 2024-01-01 2024-03-31 0001562733 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001562733 us-gaap:CommonStockMember 2024-03-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001562733 us-gaap:TreasuryStockCommonMember 2024-03-31 0001562733 us-gaap:RetainedEarningsMember 2024-03-31 0001562733 2024-03-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001562733 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001562733 us-gaap:CommonStockMember 2024-06-30 0001562733 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001562733 us-gaap:TreasuryStockCommonMember 2024-06-30 0001562733 us-gaap:RetainedEarningsMember 2024-06-30 0001562733 2024-06-30 0001562733 us-gaap:CommonStockMember 2024-12-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001562733 us-gaap:TreasuryStockCommonMember 2024-12-31 0001562733 us-gaap:RetainedEarningsMember 2024-12-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001562733 2025-01-01 2025-03-31 0001562733 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001562733 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001562733 us-gaap:CommonStockMember 2025-03-31 0001562733 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001562733 us-gaap:TreasuryStockCommonMember 2025-03-31 0001562733 us-gaap:RetainedEarningsMember 2025-03-31 0001562733 2025-03-31 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001562733 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001562733 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001562733 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001562733 us-gaap:CommonStockMember 2025-06-30 0001562733 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001562733 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001562733 us-gaap:TreasuryStockCommonMember 2025-06-30 0001562733 us-gaap:RetainedEarningsMember 2025-06-30 0001562733 snyr:OptionsToPurchaseCommonStockMember 2025-01-01 2025-06-30 0001562733 snyr:OptionsToPurchaseCommonStockMember 2024-01-01 2024-06-30 0001562733 us-gaap:WarrantMember 2025-06-30 0001562733 snyr:HandMDCorpMember 2025-06-30 0001562733 2024-01-01 2024-12-31 0001562733 us-gaap:StockOptionMember 2025-04-01 2025-06-30 0001562733 us-gaap:StockOptionMember 2024-01-01 2024-06-30 0001562733 us-gaap:WarrantMember 2025-04-01 2025-06-30 0001562733 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001562733 snyr:PeriodendAUDUSDExchangeRateMember 2025-06-30 0001562733 snyr:PeriodendAUDUSDExchangeRateMember 2024-12-31 0001562733 snyr:PeriodendCADUSDExchangeRateMember 2025-06-30 0001562733 snyr:PeriodendCADUSDExchangeRateMember 2024-12-31 0001562733 snyr:AverageSixMonthsAUDUSDExchangeRateMember 2025-06-30 0001562733 snyr:AverageSixMonthsAUDUSDExchangeRateMember 2024-06-30 0001562733 snyr:AverageSixMonthsCADUSDExchangeRateMember 2025-06-30 0001562733 snyr:AverageSixMonthsCADUSDExchangeRateMember 2024-06-30 0001562733 snyr:AverageThreeMonthsAUDUSDExchangeRateMember 2025-06-30 0001562733 snyr:AverageThreeMonthsAUDUSDExchangeRateMember 2024-06-30 0001562733 snyr:AverageThreeMonthsCADUSDExchangeRateMember 2025-06-30 0001562733 snyr:AverageThreeMonthsCADUSDExchangeRateMember 2024-06-30 0001562733 srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-06-30 0001562733 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2024-01-01 2024-06-30 0001562733 srt:RestatementAdjustmentMember 2024-01-01 2024-06-30 0001562733 srt:ScenarioPreviouslyReportedMember 2024-04-01 2024-06-30 0001562733 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2024-04-01 2024-06-30 0001562733 srt:RestatementAdjustmentMember 2024-04-01 2024-06-30 0001562733 snyr:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0001562733 snyr:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001562733 snyr:ThreeCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0001562733 snyr:TwoCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001562733 snyr:ThreeCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0001562733 snyr:TwoCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001562733 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember snyr:TwoVendorsMember 2025-01-01 2025-06-30 0001562733 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember snyr:FourVendorsMember 2024-01-01 2024-12-31 0001562733 snyr:PurchasesMember us-gaap:SupplierConcentrationRiskMember snyr:ThreeSuppliersMember 2025-01-01 2025-06-30 0001562733 snyr:PurchasesMember us-gaap:SupplierConcentrationRiskMember snyr:OneSuppliersMember 2024-01-01 2024-06-30 0001562733 snyr:PurchasesMember us-gaap:SupplierConcentrationRiskMember snyr:OneSuppliersMember 2025-04-01 2025-06-30 0001562733 snyr:PurchasesMember us-gaap:SupplierConcentrationRiskMember snyr:OneSuppliersMember 2024-04-01 2024-06-30 0001562733 srt:ChiefExecutiveOfficerMember 2025-04-01 2025-06-30 0001562733 srt:ChiefExecutiveOfficerMember 2024-04-01 2024-06-30 0001562733 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-06-30 0001562733 srt:ChiefExecutiveOfficerMember 2024-01-01 2024-06-30 0001562733 us-gaap:RelatedPartyMember 2025-06-30 0001562733 us-gaap:RelatedPartyMember 2024-12-31 0001562733 srt:ChiefExecutiveOfficerMember 2025-06-30 0001562733 us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001562733 us-gaap:RelatedPartyMember 2025-01-01 2025-06-30 0001562733 us-gaap:RelatedPartyMember 2024-01-01 2024-06-30 0001562733 us-gaap:RelatedPartyMember 2025-04-01 2025-06-30 0001562733 us-gaap:RelatedPartyMember 2024-04-01 2024-06-30 0001562733 snyr:KnightTherapeuticsMember 2016-12-23 2016-12-23 0001562733 snyr:KnightTherapeuticsMember 2016-12-23 0001562733 snyr:KnightTherapeuticsMember 2025-06-30 0001562733 snyr:KnightTherapeuticsMember 2024-12-31 0001562733 snyr:RoyaltyDistributionAgreementMember 2025-01-01 2025-06-30 0001562733 snyr:RoyaltyDistributionAgreementMember 2024-01-01 2024-12-31 0001562733 snyr:SecondAmendmentMember 2017-08-09 0001562733 snyr:AugustNineTwoZeroOneSevenLoanMember 2025-04-01 2025-06-30 0001562733 snyr:AugustNineTwoZeroOneSevenLoanMember 2024-04-01 2024-06-30 0001562733 snyr:AugustNineTwoZeroOneSevenLoanMember 2025-01-01 2025-06-30 0001562733 snyr:AugustNineTwoZeroOneSevenLoanMember 2024-01-01 2024-06-30 0001562733 snyr:August92017LoanMember 2025-05-29 0001562733 2025-05-29 2025-05-29 0001562733 snyr:PreFundedWarrantMember us-gaap:CommonStockMember 2025-06-11 0001562733 snyr:PreFundedWarrantMember 2025-06-11 2025-06-11 0001562733 snyr:PreFundedWarrantMember 2025-06-11 0001562733 2025-06-11 2025-06-11 0001562733 snyr:AugustNineTwoZeroOneSevenLoanMember 2024-01-01 2024-12-31 0001562733 snyr:FebruaryTenTwoZeroTwoTwoLoanMember 2022-02-10 0001562733 snyr:SecurityAgreementMember 2025-06-30 0001562733 snyr:SecuritiesPurchaseAgreementsMember 2022-03-08 2022-03-08 0001562733 snyr:March82022LoansMember 2022-03-08 2022-03-08 0001562733 snyr:SecuritiesPurchaseAgreementsMember 2022-03-08 0001562733 snyr:MayAndJune2025LoanMember 2025-01-01 2025-06-30 0001562733 srt:MinimumMember 2025-06-30 0001562733 srt:MinimumMember snyr:March82022LoansMember 2025-06-30 0001562733 snyr:March82022LoansMember 2025-06-30 0001562733 snyr:ReleaseAgreementMember 2025-01-01 2025-06-30 0001562733 snyr:ReleaseAgreementMember 2024-01-01 2024-12-31 0001562733 snyr:JackRossMember 2025-01-01 2025-06-30 0001562733 snyr:DecemberTwoEightTwoZeroTwoThreeLoanMember 2023-12-28 0001562733 snyr:DecemberTwoEightTwoZeroTwoThreeLoanMember 2023-12-28 2023-12-28 0001562733 snyr:DecemberTwoEightTwoZeroTwoThreeLoanMember 2025-06-30 0001562733 snyr:DecemberTwoEightTwoZeroTwoThreeLoanMember 2024-06-30 0001562733 snyr:DecemberTwoEightTwoZeroTwoThreeLoanMember 2025-01-01 2025-06-30 0001562733 snyr:DecemberTwoEightTwoZeroTwoThreeLoanMember 2024-01-01 2024-12-31 0001562733 snyr:MarchTwoSevenTwoZeroTwoFourLoanMember 2025-06-30 0001562733 snyr:MarchTwoSevenTwoZeroTwoFourLoanMember 2024-06-30 0001562733 snyr:MarchTwoSevenTwoZeroTwoFourLoanMember 2025-01-01 2025-06-30 0001562733 snyr:MarchTwoSevenTwoZeroTwoFourLoanMember 2024-01-01 2024-12-31 0001562733 snyr:MayOneTwoZeroFourLoanMember 2024-05-01 0001562733 snyr:MayOneTwoZeroFourLoanMember 2024-05-01 2024-05-01 0001562733 snyr:MayOneTwoZeroFourLoanMember 2025-04-01 2025-06-30 0001562733 snyr:MayOneTwoZeroFourLoanMember 2025-01-01 2025-06-30 0001562733 snyr:MayOneTwoZeroFourLoanMember 2024-01-01 2024-12-31 0001562733 snyr:May222024Member 2024-05-22 0001562733 snyr:May222024Member 2024-05-22 2024-05-22 0001562733 snyr:May222024Member snyr:ShopifyCapitalIncMember 2024-05-22 2024-05-22 0001562733 snyr:May222024Member 2025-06-30 0001562733 snyr:May222024Member 2025-01-01 2025-06-30 0001562733 snyr:May222024Member 2024-01-01 2024-06-30 0001562733 snyr:May222024Member 2024-01-01 2024-12-31 0001562733 snyr:December52024LoanMember 2024-12-05 0001562733 snyr:December52024LoanMember snyr:CedarAdvanceLLCMember 2024-12-05 2024-12-05 0001562733 2024-12-05 2024-12-05 0001562733 snyr:December52024LoanMember 2024-12-05 2024-12-05 0001562733 snyr:CedarAdvanceLLCMember 2024-12-05 2024-12-05 0001562733 snyr:December52024LoanMember 2024-01-01 2024-12-31 0001562733 snyr:February2025LoanMember 2025-01-29 0001562733 2025-01-29 2025-01-29 0001562733 snyr:February2025LoanMember 2025-01-29 2025-01-29 0001562733 snyr:February2025LoanMember 2025-04-01 2025-06-30 0001562733 snyr:February2025LoanMember 2025-01-01 2025-06-30 0001562733 snyr:February2025LoanMember 2025-06-30 2025-06-30 0001562733 2025-05-30 0001562733 snyr:DelayedDrawFacilityMember 2025-05-30 0001562733 2025-05-30 2025-05-30 0001562733 srt:ScenarioForecastMember 2026-01-01 2026-01-01 0001562733 srt:ScenarioForecastMember 2026-04-01 2026-04-01 0001562733 srt:ScenarioForecastMember 2026-07-01 2026-07-01 0001562733 srt:ScenarioForecastMember 2026-10-01 2026-10-01 0001562733 srt:ScenarioForecastMember 2027-01-01 2027-01-01 0001562733 snyr:May2025LoanMember 2025-05-30 2025-05-30 0001562733 snyr:May2025LoanMember 2025-01-01 2025-06-30 0001562733 snyr:May2025LoanMember 2025-06-30 0001562733 snyr:May2025LoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2025-01-01 2025-06-30 0001562733 snyr:NotesPayableMember 2025-06-30 0001562733 snyr:NotesPayableMember 2024-12-31 0001562733 snyr:August92017LoanMember 2025-06-30 0001562733 snyr:August92017LoanMember 2024-12-31 0001562733 snyr:NotesPayableOneMember 2025-06-30 0001562733 snyr:NotesPayableOneMember 2024-12-31 0001562733 snyr:NotesMember 2025-06-30 0001562733 snyr:NotesMember 2024-12-31 0001562733 snyr:NotesPayableTwoMember 2025-06-30 0001562733 snyr:NotesPayableTwoMember 2024-12-31 0001562733 snyr:December282023LoanMember 2025-06-30 0001562733 snyr:December282023LoanMember 2024-12-31 0001562733 snyr:NotesPayableThreeMember 2025-06-30 0001562733 snyr:NotesPayableThreeMember 2024-12-31 0001562733 snyr:MarchTwoSevenTwoZeroTwoFourLoanMember 2025-06-30 0001562733 snyr:MarchTwoSevenTwoZeroTwoFourLoanMember 2024-12-31 0001562733 snyr:NotesPayableFourMember 2025-06-30 0001562733 snyr:NotesPayableFourMember 2024-12-31 0001562733 snyr:NotesPayableFiveMember 2025-06-30 0001562733 snyr:NotesPayableFiveMember 2024-12-31 0001562733 snyr:February2025LoanMember 2025-06-30 0001562733 snyr:February2025LoanMember 2024-12-31 0001562733 snyr:NotesPayableSixMember 2025-06-30 0001562733 snyr:NotesPayableSixMember 2024-12-31 0001562733 snyr:May2025LoanMember 2025-06-30 0001562733 snyr:May2025LoanMember 2024-12-31 0001562733 snyr:NotesPayableSevenMember 2025-06-30 0001562733 snyr:NotesPayableSevenMember 2024-12-31 0001562733 snyr:March272024LoanMember 2025-06-30 0001562733 us-gaap:ServiceMember 2025-01-01 2025-06-30 0001562733 us-gaap:ServiceMember 2024-01-01 2024-12-31 0001562733 us-gaap:WarrantMember us-gaap:RelatedPartyMember 2025-06-30 0001562733 snyr:ReleaseAgreementMember 2025-06-30 2025-06-30 0001562733 us-gaap:CommonStockMember 2025-06-30 0001562733 us-gaap:CommonStockMember 2024-12-31 0001562733 us-gaap:WarrantMember 2025-06-30 0001562733 srt:WeightedAverageMember 2025-06-30 0001562733 srt:WeightedAverageMember 2025-01-01 2025-06-30 0001562733 us-gaap:WarrantMember snyr:ElevenPointSevenZeroMember 2025-06-30 0001562733 us-gaap:WarrantMember 2024-12-31 0001562733 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001562733 country:US 2025-04-01 2025-06-30 0001562733 country:US 2024-04-01 2024-06-30 0001562733 snyr:ForeignCountriesMember 2025-04-01 2025-06-30 0001562733 snyr:ForeignCountriesMember 2024-04-01 2024-06-30 0001562733 country:US 2025-01-01 2025-06-30 0001562733 country:US 2024-01-01 2024-06-30 0001562733 snyr:ForeignCountriesMember 2025-01-01 2025-06-30 0001562733 snyr:ForeignCountriesMember 2024-01-01 2024-06-30 0001562733 snyr:NutraceuticalsMember 2025-04-01 2025-06-30 0001562733 snyr:NutraceuticalsMember 2024-04-01 2024-06-30 0001562733 snyr:LicenseRevenueMember 2025-04-01 2025-06-30 0001562733 snyr:LicenseRevenueMember 2024-04-01 2024-06-30 0001562733 snyr:NutraceuticalsMember 2025-01-01 2025-06-30 0001562733 snyr:NutraceuticalsMember 2024-01-01 2024-06-30 0001562733 snyr:LicenseRevenueMember 2025-01-01 2025-06-30 0001562733 snyr:LicenseRevenueMember 2024-01-01 2024-06-30 0001562733 snyr:OnlineMember 2025-04-01 2025-06-30 0001562733 snyr:OnlineMember 2024-04-01 2024-06-30 0001562733 snyr:RetailerPromotionsMember 2025-04-01 2025-06-30 0001562733 snyr:RetailerPromotionsMember 2024-04-01 2024-06-30 0001562733 snyr:OnlineMember 2025-01-01 2025-06-30 0001562733 snyr:OnlineMember 2024-01-01 2024-06-30 0001562733 us-gaap:RetailMember 2025-01-01 2025-06-30 0001562733 us-gaap:RetailMember 2024-01-01 2024-06-30 0001562733 snyr:RetailerPromotionsMember 2025-04-01 2025-06-30 0001562733 snyr:RetailerPromotionsMember 2024-04-01 2024-06-30 0001562733 snyr:FreightAndFulfillmentMember 2025-04-01 2025-06-30 0001562733 snyr:FreightAndFulfillmentMember 2024-04-01 2024-06-30 0001562733 snyr:OnlineMarketingMember 2025-04-01 2025-06-30 0001562733 snyr:OnlineMarketingMember 2024-04-01 2024-06-30 0001562733 snyr:SalariesAndBenefitsMarketingMember 2025-04-01 2025-06-30 0001562733 snyr:SalariesAndBenefitsMarketingMember 2024-04-01 2024-06-30 0001562733 snyr:OtherSellingAndMarketingMember 2025-04-01 2025-06-30 0001562733 snyr:OtherSellingAndMarketingMember 2024-04-01 2024-06-30 0001562733 snyr:ITExpensesMember 2025-04-01 2025-06-30 0001562733 snyr:ITExpensesMember 2024-04-01 2024-06-30 0001562733 snyr:SalariesAndBenefitsNonMarketingMember 2025-04-01 2025-06-30 0001562733 snyr:SalariesAndBenefitsNonMarketingMember 2024-04-01 2024-06-30 0001562733 snyr:ProfessionalFeesMember 2025-04-01 2025-06-30 0001562733 snyr:ProfessionalFeesMember 2024-04-01 2024-06-30 0001562733 snyr:TravelMember 2025-04-01 2025-06-30 0001562733 snyr:TravelMember 2024-04-01 2024-06-30 0001562733 snyr:OtherGeneralAndAdministrativeExpensesMember 2025-04-01 2025-06-30 0001562733 snyr:OtherGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0001562733 snyr:AmortizationMember 2025-04-01 2025-06-30 0001562733 snyr:AmortizationMember 2024-04-01 2024-06-30 0001562733 snyr:RetailerPromotionsMember 2025-01-01 2025-06-30 0001562733 snyr:RetailerPromotionsMember 2024-01-01 2024-06-30 0001562733 snyr:FreightAndFulfillmentMember 2025-01-01 2025-06-30 0001562733 snyr:FreightAndFulfillmentMember 2024-01-01 2024-06-30 0001562733 snyr:OnlineMarketingMember 2025-01-01 2025-06-30 0001562733 snyr:OnlineMarketingMember 2024-01-01 2024-06-30 0001562733 snyr:SalariesAndBenefitsMarketingMember 2025-01-01 2025-06-30 0001562733 snyr:SalariesAndBenefitsMarketingMember 2024-01-01 2024-06-30 0001562733 snyr:OtherSellingAndMarketingMember 2025-01-01 2025-06-30 0001562733 snyr:OtherSellingAndMarketingMember 2024-01-01 2024-06-30 0001562733 snyr:ITExpensesMember 2025-01-01 2025-06-30 0001562733 snyr:ITExpensesMember 2024-01-01 2024-06-30 0001562733 snyr:SalariesAndBenefitsNonMarketingMember 2025-01-01 2025-06-30 0001562733 snyr:SalariesAndBenefitsNonMarketingMember 2024-01-01 2024-06-30 0001562733 snyr:ProfessionalFeesMember 2025-01-01 2025-06-30 0001562733 snyr:ProfessionalFeesMember 2024-01-01 2024-06-30 0001562733 snyr:TravelMember 2025-01-01 2025-06-30 0001562733 snyr:TravelMember 2024-01-01 2024-06-30 0001562733 snyr:OtherGeneralAndAdministrativeExpensesMember 2025-01-01 2025-06-30 0001562733 snyr:OtherGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0001562733 snyr:AmortizationMember 2025-01-01 2025-06-30 0001562733 snyr:AmortizationMember 2024-01-01 2024-06-30 0001562733 country:US 2025-06-30 0001562733 country:US 2024-12-31 0001562733 snyr:ForeignCountriesMember 2025-06-30 0001562733 snyr:ForeignCountriesMember 2024-12-31 0001562733 snyr:March272024LoanMember us-gaap:SubsequentEventMember 2025-07-01 2025-07-31 0001562733 snyr:March272024LoanMember us-gaap:SubsequentEventMember 2025-07-31 0001562733 snyr:February2025LoanMember us-gaap:SubsequentEventMember 2025-07-01 2025-07-31 0001562733 snyr:March82022LoansMember us-gaap:SubsequentEventMember 2025-07-01 2025-07-31 0001562733 snyr:May2025LoanMember us-gaap:SubsequentEventMember 2025-07-01 2025-07-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure snyr:Segment iso4217:CAD

Exhibit 31.1

 

CERTIFICATIONS

 

I, Jack Ross, certify that:

 

1.I have reviewed this Form 10-Qquarterly report of Synergy CHC Corp. for the quarter ended June 30, 2025;

 

2.Based on my knowledge, this reportdoes not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in lightof the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financialstatements, and other financial information included in this report, fairly present in all material respects the financial condition,results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.I am responsible for establishingand maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control overfinancial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  SYNERGY CHC CORP.
     
Date: August 14, 2025 By: /s/ Jack Ross
  Name:  Jack Ross
  Title: Chief Executive Officer and Chairman
    (Principal Executive Officer)

 

 

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Jaime Fickett, certify that:

 

1.I have reviewed this Form 10-Qquarterly report of Synergy CHC Corp. for the quarter ended June 30, 2025;

 

2.Based on my knowledge, this reportdoes not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in lightof the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financialstatements, and other financial information included in this report, fairly present in all material respects the financial condition,results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.I am responsible for establishingand maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control overfinancial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  SYNERGY CHC CORP.
     
Date: August 14, 2025 By: /s/ Jaime Fickett
  Name:  Jaime Fickett
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEYACT OF 2002

 

In connection with the quarterly report of SynergyCHC Corp. (the “Company”) on Form 10-Q for the quarter ended June 30, 2025, as filed with the Securities and Exchange Commission(the “Report”), the undersigned principal executive officer of the Company, hereby certifies pursuant to 18 U.S.C. Section1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

  SYNERGY CHC CORP.
     
Date: August 14, 2025 By: /s/ Jack Ross
  Name:  Jack Ross
  Title: Chief Executive Officer and Chairman
    (Principal Executive Officer)

 

 

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION1350

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEYACT OF 2002

 

In connection with the quarterly report of SynergyCHC Corp. (the “Company”) on Form 10-Q for the quarter ended June 30, 2025, as filed with the Securities and Exchange Commission(the “Report”), the undersigned principal financial officer of the Company, hereby certifies pursuant to 18 U.S.C. Section1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

  SYNERGY CHC CORP.
     
Date: August 14, 2025 By: /s/ Jaime Fickett
  Name:  Jaime Fickett
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)